Molecular barcoding at opposite transcript ends

By barcoding nucleic acid targets with oligonucleotides and extending stem-loops, combined with reverse transcription and PCR amplification, the problem of accuracy in determining the number of nucleic acid targets was solved, achieving accurate counting of nucleic acid targets and precision in gene expression measurement.

CN118910215APending Publication Date: 2024-11-08BECTON DICKINSON & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410983791.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-05-03
Filing Date
2019-05-01
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing technologies struggle to accurately determine the number of nucleic acid targets in a sample, especially when the number of molecules is extremely small. PCR amplification is subject to random replication bias, leading to inaccurate gene expression measurements.

Method used

Oligonucleotide barcoding was used to barcode nucleic acid targets. The number of nucleic acid targets was determined by forming stem loops and extending the 3' ends, combined with reverse transcription and PCR amplification. Multiple oligonucleotide barcodes were attached to the nucleic acid targets to form stem loops. The stem loops were extended to generate nucleic acid molecules containing molecular markers and their complements, which were then amplified and sequenced.

Benefits of technology

By correcting PCR amplification bias through random barcoding, the number of nucleic acid targets can be accurately counted, thus improving the accuracy of gene expression measurement.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910215A_ABST
    Figure CN118910215A_ABST
Patent Text Reader

Abstract

The invention relates to molecular barcoding at opposite transcript ends. Disclosed herein are systems, methods, compositions, and kits for molecular barcoding at the 5'end of a nucleic acid target. After barcoding a nucleic acid target using an oligonucleotide barcode comprising a target binding region and a molecular marker to produce a barcoded nucleic acid molecule, an oligonucleotide comprising a complement of the target binding region may be added to produce a barcoded nucleic acid molecule comprising the target binding region and the complement of the target binding region. A stem loop is formed by intramolecular hybridization of the barcoded nucleic acid molecule, which can be extended to produce an extended barcoded nucleic acid molecule comprising the molecular marker and a complement of the molecular marker.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an application filed on May 1, 2019, with application number 201980037342.1 and invention name “Molecular barcoding at relative transcript ends”.

[0002] Related Applications

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 666,506, filed May 3, 2018, which is incorporated herein by reference in its entirety. Technical Field

[0004] The present disclosure relates generally to the field of molecular biology, and in particular to multi-omics analysis using molecular barcoding. Background Art

[0005] Methods and techniques such as molecular barcoding are useful for single-cell transcriptomic analysis, particularly using, for example, reverse transcription, polymerase chain reaction (PCR) amplification, and next-generation sequencing (NGS) to decipher gene expression profiles to determine the state of a cell. Molecular barcoding can also be used for single-cell proteomic analysis. Summary of the invention

[0006] Disclosed herein are methods for attaching an oligonucleotide barcode to a target in a sample.For example, the target can comprise, consist essentially of, or consist of a nucleic acid target. In some embodiments, the method includes: barcoding copies of a nucleic acid target in a sample using multiple oligonucleotide barcodes to produce multiple barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the multiple oligonucleotide barcodes comprise different molecular marker sequences; attaching an oligonucleotide comprising a complement of the target binding region to the multiple barcoded nucleic acid molecules to produce multiple barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and the complement of the target binding region within each of the multiple barcoded nucleic acid molecules to form a stem loop; and extending the 3' ends of the multiple barcoded nucleic acid molecules to extend the stem loop to produce multiple extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the molecular marker and a complement of the molecular marker. Optionally, the method further includes amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules. Attaching an oligonucleotide comprising a complement of a target binding region may include attaching an oligonucleotide to a plurality of amplified barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a target binding region and a complement of the target binding region. Optionally, the method further includes amplifying a plurality of extended barcoded nucleic acid molecules. The number of nucleic acid targets in the sample can be determined after amplifying a plurality of extended barcoded nucleic acid molecules. In some embodiments, the method includes: determining the number of nucleic acid targets in the sample based on the number of molecular markers with different sequences associated with a plurality of extended barcoded nucleic acid molecules, their complementary sequences, or a combination thereof. In some embodiments, the method includes: determining the number of nucleic acid targets in the sample based on the number of molecular markers with different sequences associated with a plurality of extended barcoded nucleic acid molecules.

[0007] Disclosed herein are methods for determining the number of targets in a sample. For example, the target can comprise, consist essentially of, or consist of a nucleic acid. In some embodiments, the method comprises: barcoding a copy of a nucleic acid target in a sample using a plurality of oligonucleotide barcodes to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and The method further comprises amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules. Attaching an oligonucleotide comprising a complement of the target binding region may include attaching an oligonucleotide to a plurality of amplified barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a target binding region and a complement of the target binding region. Optionally, the method further comprises amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules. Attaching an oligonucleotide comprising a complement of the target binding region may include attaching an oligonucleotide to a plurality of amplified barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a target binding region and a complement of the target binding region. Optionally, the method further comprises amplifying a plurality of extended barcoded nucleic acid molecules. The number of nucleic acid targets in the sample can be determined after amplifying the plurality of extended barcoded nucleic acid molecules. In some embodiments, the method comprises determining the number of nucleic acid targets in the sample based on the number of molecular tags with different sequences, their complements, or a combination thereof, associated with the plurality of extended barcoded nucleic acid molecules.

[0008] In some embodiments, any of the methods described herein include barcoding copies of multiple targets, comprising: contacting the copies of the nucleic acid target with the multiple oligonucleotide barcodes, wherein each of the multiple oligonucleotide barcodes comprises a target binding region capable of hybridizing with the nucleic acid target; and extending the copies of the nucleic acid target hybridized with the oligonucleotide barcodes to produce multiple barcoded nucleic acid molecules. In some embodiments, any of the methods described herein include: barcoding the copies of the multiple targets includes: contacting the copies of the nucleic acid target with the multiple oligonucleotide barcodes, wherein each of the multiple oligonucleotide barcodes comprises a target binding region. The target binding region can hybridize with the nucleic acid target. The method can further include extending the copies of the nucleic acid target hybridized with the oligonucleotide barcodes to produce multiple barcoded nucleic acid molecules.

[0009] In some embodiments, any of the methods described herein comprises: amplifying a plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules, wherein attaching an oligonucleotide comprising a complement of a target binding region comprises: attaching an oligonucleotide comprising a complement of a target binding region to the plurality of amplified barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a target binding region and a complement of the target binding region.

[0010] In some embodiments, any of the methods described herein includes: amplifying a plurality of extended barcoded nucleic acid molecules to produce a plurality of singly labeled nucleic acid molecules, each singly labeled nucleic acid molecule comprising a complement of a molecular marker, wherein determining the number of nucleic acid targets in a sample includes: determining the number of nucleic acid targets in the sample based on the number of complementary sequences of the molecular markers having different sequences associated with the plurality of singly labeled nucleic acid molecules.

[0011] In some embodiments, the method includes: amplifying multiple extended barcoded nucleic acid molecules to produce multiple copies of the extended barcoded nucleic acid molecules, wherein determining the number of nucleic acid targets in the sample includes: determining the number of nucleic acid targets in the sample based on the number of complementary sequences of molecular markers with different sequences associated with the copies of the multiple extended barcoded nucleic acid molecules.

[0012] Disclosed herein is a method for determining the number of nucleic acid targets in a sample. In some embodiments, the method includes: contacting a copy of a nucleic acid target in a sample with a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region capable of hybridizing with the nucleic acid target, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; extending a copy of the nucleic acid target hybridized with the oligonucleotide barcode to produce a plurality of nucleic acid molecules, each nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target; amplifying a plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of amplified barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target; The method comprises the steps of: generating a barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and the complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem loop; extending the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem loop to generate a plurality of extended barcoded nucleic acid molecules, each of which comprises the molecular tag and a complement of the molecular tag; amplifying the plurality of extended barcoded nucleic acid molecules to generate a plurality of single-labeled nucleic acid molecules, each of which comprises the complement of the molecular tag; and determining the number of nucleic acid targets in the sample based on the number of complementary sequences of the molecular tags having different sequences associated with the plurality of single-labeled nucleic acid molecules.

[0013] In some embodiments, for any of the methods described herein, after extending the 3' ends of a plurality of barcoded nucleic acid molecules, hybridizing the molecular marker with the complement of the molecular marker, the method includes denaturing the plurality of extended barcoded nucleic acid molecules, and then amplifying the plurality of extended barcoded nucleic acid molecules to produce a plurality of single labeled nucleic acid molecules. Contacting a copy of a nucleic acid target in a sample may include contacting a copy of a plurality of nucleic acid targets with a plurality of oligonucleotide barcodes. Extending a copy of a nucleic acid target may include extending a copy of a plurality of nucleic acid targets hybridized with an oligonucleotide barcode to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence complementary to at least a portion of one of the plurality of nucleic acid targets. Determining the number of nucleic acid targets may include determining the number of each of the plurality of nucleic acid targets in a sample based on the number of complementary sequences of the molecular markers having different sequences associated with the single labeled nucleic acid molecules of the plurality of single labeled nucleic acid molecules comprising the sequence of each of the plurality of nucleic acid targets. The sequence of each of the plurality of nucleic acid targets may include a subsequence of each of the plurality of nucleic acid targets.

[0014] In some embodiments, for any of the methods described herein, the sequence of the nucleic acid target in the plurality of barcoded nucleic acid molecules comprises a subsequence of the nucleic acid target. The target binding region may comprise a gene-specific sequence. Attaching an oligonucleotide comprising a complement of the target binding region may comprise connecting an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules.

[0015] In some embodiments, for any of the methods described herein, the target binding region may comprise a poly (dT) sequence, wherein attaching an oligonucleotide comprising a complement of the target binding region comprises: adding multiple adenosine monophosphates to the multiple barcoded nucleic acid molecules using terminal deoxynucleotidyl transferase.

[0016] In some embodiments, for any of the methods described herein, extending a copy of a nucleic acid target hybridized to an oligonucleotide barcode may include reverse transcribing a copy of a nucleic acid target hybridized to an oligonucleotide barcode to generate a plurality of barcoded complementary deoxyribonucleic acid (cDNA) molecules. Extending a copy of a nucleic acid target hybridized to an oligonucleotide barcode may include extending a copy of a nucleic acid target hybridized to an oligonucleotide barcode using a DNA polymerase lacking at least one of a 5' to 3' exonuclease activity and a 3' to 5' exonuclease activity. The DNA polymerase may comprise a Klenow fragment.

[0017] In some embodiments, any of the methods described herein includes obtaining sequence information for the plurality of extended barcoded nucleic acid molecules. Obtaining sequence information can include attaching sequencing adaptors to the plurality of extended barcoded nucleic acid molecules.

[0018] In some embodiments, for any of the methods described herein, the complement of the target binding region may comprise the reverse complement of the target binding region. The complement of the target binding region may comprise the complement of the target binding region. The complement of the molecular marker may comprise the reverse complement of the molecular marker. The complement of the molecular marker may comprise the complement of the molecular marker.

[0019] In some embodiments, for any of the methods described herein, a plurality of barcoded nucleic acid molecules may comprise barcoded deoxyribonucleic acid (DNA) molecules. Barcoded nucleic acid molecules may comprise barcoded ribonucleic acid (RNA) molecules. Nucleic acid targets may comprise nucleic acid molecules. Nucleic acid molecules may comprise ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA comprising a poly (A) tail, or any combination thereof.

[0020] In some embodiments, for any of the methods described herein, the nucleic acid target may comprise a cellular component binding agent. The nucleic acid molecule may be associated with a cellular component binding agent. The method may include: dissociating the nucleic acid molecule and the cellular component binding agent.

[0021] In some embodiments, for any of the methods described herein, each molecular marker of a plurality of oligonucleotide barcodes comprises at least 6 nucleotides. The oligonucleotide barcodes may comprise the same sample marker. Each sample marker of a plurality of oligonucleotide barcodes may comprise at least 6 nucleotides. The oligonucleotide barcodes may comprise the same cell marker. Each cell marker of a plurality of oligonucleotide barcodes may comprise at least 6 nucleotides.

[0022] In some embodiments, for any of the methods described herein, when the target binding region within each of the plurality of barcoded nucleic acid molecules and the complement of the target binding region are hybridized to form a stem-loop, at least one of the plurality of barcoded nucleic acid molecules is associated with a solid support. When the target binding region within each of the plurality of barcoded nucleic acid molecules and the complement of the target binding region are hybridized to form a stem-loop, at least one of the plurality of barcoded nucleic acid molecules can be dissociated from the solid support. When the target binding region within each of the plurality of barcoded nucleic acid molecules and the complement of the target binding region are hybridized to form a stem-loop, at least one of the plurality of barcoded nucleic acid molecules can be associated with a solid support.

[0023] In some embodiments, for any of the methods described herein, when the 3' ends of a plurality of barcoded nucleic acid molecules are extended to extend the stem loops to produce a plurality of extended barcoded nucleic acid molecules (each extended barcoded nucleic acid molecule comprises a molecular tag and a complement of the molecular tag), at least one of the plurality of barcoded nucleic acid molecules is associated with a solid support. When the 3' ends of a plurality of barcoded nucleic acid molecules are extended to extend the stem loops to produce a plurality of extended barcoded nucleic acid molecules (each extended barcoded nucleic acid molecule comprises a molecular tag and a complement of the molecular tag), at least one of the plurality of barcoded nucleic acid molecules may be dissociated from the solid support. When the 3' ends of a plurality of barcoded nucleic acid molecules are extended to extend the stem loops to produce a plurality of extended barcoded nucleic acid molecules (each extended barcoded nucleic acid molecule comprises a molecular tag and a complement of the molecular tag), at least one of the plurality of barcoded nucleic acid molecules may be associated with a solid support. The solid support may comprise synthetic particles. The solid support may comprise a flat surface (e.g., a slide, such as a microscope slide and a cover slip). In some embodiments, the solutions described herein may be dispensed in a dispensing area containing no more than one cell. The dispensing area may include at least one of a droplet, a well (e.g., a microwell), such as a well on a substrate, or a chamber of a fluidic device such as a microfluidic device. The droplet may comprise a hydrogel.

[0024] In some embodiments, for any of the methods described herein, at least one of the plurality of barcoded nucleic acid molecules is in solution when the target binding region and the complement of the target binding region within each of the plurality of barcoded nucleic acid molecules are hybridized to form a stem-loop. At least one of the plurality of barcoded nucleic acid molecules can be in solution when the 3' ends of the plurality of barcoded nucleic acid molecules are extended to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each of which comprises a molecular tag and a complement of the molecular tag.

[0025] In some embodiments, for any of the methods described herein, the sample comprises a single cell, and the method comprises associating a synthetic particle comprising a plurality of oligonucleotide barcodes with a single cell in the sample. The method may comprise, after associating the synthetic particle with the single cell, lysing the single cell. Lysing the single cell may comprise heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof. The synthetic particle and the single cell may be in the same well. The synthetic particle and the single cell may be in the same drop.

[0026] In some embodiments, for any one of the methods described herein, at least one of a plurality of oligonucleotide barcodes can be fixed on a synthetic particle. At least one of a plurality of oligonucleotide barcodes can be partially fixed on a synthetic particle. At least one of a plurality of oligonucleotide barcodes can be enclosed in a synthetic particle. At least one of a plurality of oligonucleotide barcodes can be partially enclosed in a synthetic particle. The synthetic particle can be destructible. The synthetic particle can include beads. The beads can include cross-linked agarose (Sepharose) beads, streptavidin beads, agarose beads, magnetic beads, conjugated beads, protein A conjugated beads, protein G conjugated beads, protein A / G conjugated beads, protein L conjugated beads, oligo (dT) conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads or any combination thereof. The synthetic particles may comprise a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof. The synthetic particles may comprise destructible hydrogel particles. Each of the plurality of oligonucleotide barcodes may comprise a linker functional group. The synthetic particles may comprise a solid support functional group. The support functional group and the linker functional group may be associated with each other. The linker functional group and the support functional group may be individually selected from the group consisting of C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof.

[0027] Disclosed herein is a kit for attaching an oligonucleotide barcode to a target in a sample, determining the number of targets in a sample and / or determining the number of nucleic acid targets in a sample. In some embodiments, the kit includes: a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; a terminal deoxynucleotidyl transferase or a ligase; and a DNA polymerase lacking at least one of a 5' to 3' exonuclease activity and a 3' to 5' exonuclease activity. The kit may further comprise a plurality of oligonucleotides, the plurality of oligonucleotides comprising a complement of the target binding region. The plurality of oligonucleotides comprising the complement of the target binding region are configured to be attached to the 3' end of a DNA molecule, such as a cDNA molecule. The DNA polymerase may comprise a Klenow fragment. The kit may comprise a buffer. The kit may comprise a column. The kit may comprise one or more reagents for a reverse transcription reaction. The kit may comprise one or more reagents for an amplification reaction.

[0028] In some embodiments, for any kit or method described herein, the target binding region comprises a gene-specific sequence, an oligo (dT) sequence, a random polymer, or any combination thereof. The oligonucleotide barcode may comprise the same sample marker and / or the same cell marker. Each sample marker and / or cell marker of a plurality of oligonucleotide barcodes may comprise at least 6 nucleotides. Each molecular marker of a plurality of oligonucleotide barcodes may comprise at least 6 nucleotides.

[0029] In some embodiments, for any kit or method described herein, at least one of a plurality of oligonucleotide barcodes is fixed on a synthetic particle. At least one of a plurality of oligonucleotide barcodes may be partially fixed on a synthetic particle. At least one of a plurality of oligonucleotide barcodes may be enclosed in a synthetic particle. At least one of a plurality of oligonucleotide barcodes may be partially enclosed in a synthetic particle. The synthetic particle may be destructible. The synthetic particle may include beads. The beads may include cross-linked agarose (Sepharose) beads, streptavidin beads, agarose beads, magnetic beads, conjugated beads, protein A conjugated beads, protein G conjugated beads, protein A / G conjugated beads, protein L conjugated beads, oligo (dT) conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads or any combination thereof. The synthetic particles may comprise a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof. The synthetic particles may comprise destructible hydrogel particles. Each of the plurality of oligonucleotide barcodes may comprise a linker functional group. The synthetic particles may comprise a solid support functional group. The support functional group and the linker functional group may be associated with each other. The linker functional group and the support functional group may be individually selected from the group consisting of C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Non-limiting exemplary barcodes of some embodiments are shown.

[0031] Figure 2 A non-limiting exemplary workflow for barcoding and digital counting of some embodiments is shown.

[0032] Figure 3 is a schematic diagram illustrating a non-limiting exemplary process for generating an indexed library of targets barcoded at the 3' end from a plurality of targets according to some embodiments.

[0033] Figure 4A-4BSchematic diagram showing non-limiting exemplary methods of gene-specifically labeling a nucleic acid target at the 5' end of some embodiments.

[0034] Figure 5A-Figure 5B A schematic diagram is shown of a non-limiting exemplary method of labeling a nucleic acid target on the 5' end for whole transcriptome analysis of some embodiments. DETAILED DESCRIPTION

[0035] Reference is made to the accompanying drawings in the following detailed description, which form a part hereof. In the drawings, similar symbols typically identify similar components unless the context otherwise dictates. The illustrative embodiments described in the detailed description, illustrations, and claims are not intended to be limiting. Other embodiments may be employed, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It is readily understood that the aspects of the present disclosure as generally described herein and shown in the accompanying drawings may be arranged, substituted, combined, separated, and designed in a variety of different configurations, all of which are expressly encompassed herein and constitute a part of the disclosure herein.

[0036] All patents, published patent applications, other publications, and sequences in GenBank and other databases cited herein are incorporated by reference in their entirety with respect to the relevant art.

[0037] Quantifying small amounts of nucleic acids, such as messenger RNA (mRNA) molecules, is clinically important for determining, for example, which genes are expressed in cells at different stages of development or under different environmental conditions. However, determining the absolute number of nucleic acid molecules, such as mRNA molecules, is also very challenging, especially when the number of molecules is very small. One method for determining the absolute number of molecules in a sample is the digital polymerase chain reaction (PCR). Ideally, PCR produces identical copies of molecules in each cycle. However, PCR can have the disadvantage that each molecule is replicated with a random probability, and this probability varies with the PCR cycle and the gene sequence, leading to amplification bias and inaccurate gene expression measurements. Random barcodes with unique molecular markers, also called molecular indices (MIs), can be used to calculate the number of molecules and correct for amplification bias. PCR tools such as Precise TM Assay (Cellular Research, Inc. (Palo Alto, CA)) and Rhapsody TMRandom barcoding of the assay (Becton, Dickinson and Company (Franklin Lakes, NJ)) can correct for biases induced by PCR and library preparation steps by labeling mRNA during reverse transcription (RT) using molecular markers (MLs). Methods and techniques for molecular barcoding of nucleic acid target molecules at either or both of the 5' and 3' ends are needed.

[0038] Precise TM The assay can utilize a non-exhaustive pool with a large number (e.g., 6561 to 65536) of random barcodes, a unique molecular marker sequence on a poly (T) oligonucleotide, to hybridize with all poly (A)-mRNAs in the sample during the RT step. The random barcodes may include universal PCR priming sites. During RT, the target gene molecules react randomly with the random barcodes. Each target molecule can hybridize with the random barcodes to produce a random barcoded complementary ribonucleotide (cDNA) molecule. After labeling, the random barcoded cDNA molecules from the microwells of the microplate can be merged into a single tube for PCR amplification and sequencing. The raw sequencing data can be analyzed to generate the number of reads, the number of random barcodes with unique molecular marker sequences, and the number of mRNA molecules.

[0039] Disclosed herein is a method for attaching an oligonucleotide barcode to a target in a sample. In some embodiments, the method comprises: barcoding a copy of a nucleic acid target in a sample using a plurality of oligonucleotide barcodes to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and the complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem loop; and extending the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem loop to produce a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the molecular marker and a complement of the molecular marker.

[0040] Disclosed herein are methods for determining the number of targets in a sample. In some embodiments, the method comprises: barcoding copies of a nucleic acid target in a sample using a plurality of oligonucleotide barcodes to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and The invention relates to a method for producing a nucleic acid target in a sample comprising: producing a complement of the target binding region; hybridizing the target binding region and the complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem-loop; extending the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each of the extended barcoded nucleic acid molecules comprising the molecular tag and the complement of the molecular tag; and determining the number of nucleic acid targets in the sample based on the number of complementary sequences of the molecular tags with different sequences associated with the plurality of extended barcoded nucleic acid molecules.

[0041] Disclosed herein is a method for determining the number of nucleic acid targets in a sample. In some embodiments, the method includes: contacting a copy of a nucleic acid target in a sample with a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region capable of hybridizing with the nucleic acid target, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; extending a copy of the nucleic acid target hybridized with the oligonucleotide barcode to produce a plurality of nucleic acid molecules, each nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target; amplifying a plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of amplified barcoded nucleic acid molecules to produce a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target; The method comprises the steps of: generating a barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and the complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem loop; extending the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem loop to generate a plurality of extended barcoded nucleic acid molecules, each of which comprises the molecular tag and a complement of the molecular tag; amplifying the plurality of extended barcoded nucleic acid molecules to generate a plurality of single-labeled nucleic acid molecules, each of which comprises the complement of the molecular tag; and determining the number of nucleic acid targets in the sample based on the number of complementary sequences of the molecular tags having different sequences associated with the plurality of single-labeled nucleic acid molecules.

[0042] Disclosed herein is a kit for attaching an oligonucleotide barcode to a target in a sample, determining the number of targets in a sample, and / or determining the number of nucleic acid targets in a sample. In some embodiments, the kit includes: a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; a terminal deoxynucleotidyl transferase or a ligase; and a DNA polymerase lacking at least one of a 5' to 3' exonuclease activity and a 3' to 5' exonuclease activity. The DNA polymerase may comprise a Klenow fragment. The kit may comprise a buffer. The kit may comprise a column. The kit may comprise one or more reagents for a reverse transcription reaction. The kit may comprise one or more reagents for an amplification reaction.

[0043] Unless otherwise defined, technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which this disclosure belongs. Examples of references available to those of ordinary skill in the art include Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd edition, J. Wiley & Sons (New York, NY 1994); Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press (Cold Springs Harbor, NY 1989).

[0044] As used herein, in view of this specification, the term "adapter" has its customary and common meaning in the art. It can refer to a sequence that promotes the amplification or sequencing of an associated nucleic acid. The associated nucleic acid can include a target nucleic acid. The associated nucleic acid can include one or more of a spatial marker, a target mark, a sample marker, an index marker, or a barcode sequence (e.g., a molecular marker). The adaptor can be linear. The adaptor can be a pre-adenylated adaptor. The adaptor can be double-stranded or single-stranded. One or more adaptors can be located at the 5' or 3' end of the nucleic acid. When the adaptor is included in a known sequence at the 5' and 3' ends, the known sequence can be the same or different sequences. The adaptor located at the 5' and / or 3' ends of the polynucleotide can be able to hybridize with one or more oligonucleotides fixed on the surface. In some embodiments, the adaptor can include a universal sequence. The universal sequence can be a nucleotide sequence region shared by two or more nucleic acid molecules. Two or more nucleic acid molecules can also have different sequence regions. Therefore, for example, the 5' adaptor can include the same and / or universal nucleic acid sequence and the 3' adaptor can include the same and / or universal sequence. The universal sequence that can be present in different members of multiple nucleic acid molecules can allow the use of a single universal primer complementary to the universal sequence to replicate or amplify multiple different sequences. Similarly, two (e.g., a pair) or more universal sequences that can be present in different members of a nucleic acid molecule collection can allow the use of at least one, two (e.g., a pair) or more universal primers complementary to the universal sequence to replicate or amplify multiple different sequences. Therefore, the universal primer comprises a sequence that can hybridize with this universal sequence. The molecule with the target nucleic acid sequence can be modified to connect a universal adapter (e.g., a non-target nucleic acid sequence) to one or both ends of different target nucleic acid sequences. One or more universal primers that are connected to the target nucleic acid can provide a site for the hybridization of the universal primer. One or more universal primers that are connected to the target nucleic acid can be identical or different from each other.

[0045] As used herein, in view of this specification, the term "associated" or "associated with..." has its customary and ordinary meaning in the art. It can mean that two or more substances are identifiable as co-localized at a certain point in time. Association can mean that two or more substances are or have been in similar containers. Association can be an informatics association. For example, digital information about two or more substances can be stored and can be used to determine that one or more substances are co-localized at a certain point in time. Association can also be a physical association. In some embodiments, two or more associated substances are "tethered", "connected" or "fixed" to each other, or "tethered", "connected" or "fixed" to a common solid or semi-solid surface. Association can refer to a covalent or non-covalent means for connecting a label to a solid or semi-solid support such as a bead. Association can be a covalent bond between a target and a label. Association can include hybridization between two molecules (e.g., a target molecule and a label).

[0046] As used herein, in view of this specification, the term "complementary" has its customary and common meaning in the art. It can refer to the ability of accurate pairing between two nucleotides. For example, if the nucleotide at the specified position of a nucleic acid can hydrogen bond with the nucleotide of another nucleic acid, it is considered that the two nucleic acids are complementary to each other at that position. The complementarity between two single-stranded nucleic acid molecules can be "partial", in which only some nucleotides are combined, or the combination can be complete when there is overall complementarity between single-stranded molecules. If the first nucleotide sequence is complementary to the second nucleotide sequence, it can be referred to as the "complementary sequence" of the first nucleotide sequence being the second sequence. If the first nucleotide sequence is complementary to a sequence that is reverse (i.e., the order of the nucleotides is opposite) to the second sequence, it can be referred to as the "reverse complementary sequence" of the first nucleotide sequence being the second sequence. As used herein, a "complementary" sequence can refer to the "complementary" or "reverse complementary" of a sequence. It is understood from this disclosure that if a molecule can hybridize with another molecule, it can be complementary or partially complementary to the molecule being hybridized.

[0047] As used herein, the term "digital counting" may refer to a method for estimating the number of target molecules in a sample. Digital counting may include the step of determining the number of unique markers that have been associated with the target in the sample. The method may be stochastic in nature, transforming the problem of counting molecules from a problem of locating and identifying identical molecules to a series of yes / no digital questions about detecting a set of predefined markers.

[0048] As used herein, in view of this specification, the term "marker" or "multiple marks" has its customary and ordinary meaning in the art. It can refer to a nucleic acid code associated with a target in a sample. The mark can be, for example, a nucleic acid marker. The mark can be a marker that can be amplified in whole or in part. The mark can be a marker that can be sequenced in whole or in part. The mark can be a part that can be identified as different in a natural nucleic acid. The mark can be a known sequence. The mark can include a junction of a nucleic acid sequence, such as a junction of a natural sequence and a non-natural sequence. As used herein, the term "marker" can be used interchangeably with the term "index", "label" or "marker-label". The mark can convey information. For example, in different embodiments, the mark can be used to determine the sample identity, the source of the sample, the cell identity and / or the target.

[0049] As used herein, the term "non-depleting reservoirs" can refer to a pool of barcodes (e.g., random barcodes) composed of many different markers. The non-depleting reservoir can contain a large number of different barcodes, so that when the non-depleting reservoir is associated with a target library, each target is likely to be associated with a unique barcode. The uniqueness of each labeled target molecule can be determined by the statistics of random selection and depends on the number of copies of the same target molecule in the collection compared to the diversity of the marker. The size of the resulting labeled target molecule group can be determined by the random nature of the barcoding process and the number of barcodes detected, which then allows the calculation of the number of target molecules present in the original collection or sample. When the ratio of the number of copies of the target molecules present to the number of unique barcodes is low, the labeled target molecules are highly unique (i.e., the probability of labeling more than one target molecule with a specified marker is very low).

[0050] As used herein, in view of this specification, the term "nucleic acid" has its customary and common meaning in the art. It refers to a polynucleotide sequence or a fragment thereof. Nucleic acid may include nucleotides. Nucleic acid may be exogenous or endogenous to a cell. Nucleic acid may be present in a cell-free environment. Nucleic acid may be a gene or a fragment thereof. Nucleic acid may be DNA. Nucleic acid may be RNA. Nucleic acid may include one or more analogs (e.g., altered backbones, sugars, or nucleobases). Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acids, xeno nucleic acids, morpholino compounds, locked nucleic acids, diol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein connected to sugars), thiol-containing nucleotides, biotin-connected nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, braided glycosides, and wyoside. "Nucleic acid," "polynucleotide," "target polynucleotide," and "target nucleic acid" may be used interchangeably.

[0051] Nucleic acid can include one or more modifications (e.g., base modification, backbone modification) to provide nucleic acid with new or enhanced features (e.g., improved stability). Nucleic acid can include nucleic acid affinity tags. Nucleoside can be a base-sugar combination. The base portion of a nucleoside can be a heterocyclic base. The two most common types of such heterocyclic bases are purine and pyrimidine. Nucleotide can be a nucleoside further comprising a phosphate group covalently attached to the sugar portion of the nucleoside. For those nucleosides comprising pentofuranosyl, the phosphate group can be attached to the 2', 3' or 5' hydroxyl portion of the sugar. When forming nucleic acid, the phosphate group can covalently attach nucleosides adjacent to each other to form a linear polymer compound. Then, the corresponding ends of the linear polymer compound can be further connected to form a cyclic compound; however, linear compounds are generally suitable. In addition, linear compounds can have internal nucleotide base complementarity and can therefore be folded in a manner that facilitates the production of a completely or partially double-stranded compound. In nucleic acid, the phosphate group can generally be involved in forming a skeleton between nucleosides of nucleic acid. The linkage or skeleton can be a 3' to 5' phosphodiester bond.

[0052] Nucleic acid can comprise the internucleoside linkage of the backbone and / or modification of modification.The backbone of modification can include those retaining phosphorus atom in the backbone and those not having phosphorus atom in the backbone.The nucleic acid backbone of the modification suitable for containing phosphorus atom can include for example phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkylphosphonates (such as 3'-alkylenephosphonates, 5'-alkylenephosphonates, chiral phosphonates), phosphinates, phosphoramidates (including 3'-aminophosphoramidate and aminoalkylphosphoramidate, diaminophosphorate), thiophosphoramidate, alkylthiophosphonates, alkylthiophosphonic acid triesters, selenophosphates and borane phosphates with normal 3'-5' linkage, 2'-5' linkage analogs, and those with the reverse polarity of 3' to 3', 5' to 5' or 2' to 2' linkages of wherein one or more internucleotide linkages.

[0053] Nucleic acid can comprise such polynucleotide backbone, and these polynucleotide backbones are formed by short-chain alkyl or cycloalkyl nucleoside interlinkage, mixed heteroatoms and alkyl or cycloalkyl nucleoside interlinkage or one or more short-chain heteroatoms or heterocyclic nucleoside interlinkage.These backbones can include those with the following: morpholino linkage (partially formed from the sugar part of nucleoside); siloxane backbone; sulfide, sulfoxide and sulfone backbone; formyl acetyl and thioformyl acetyl backbone; methylene formyl acetyl and thioformyl acetyl backbone; core acetyl (riboacetyl) backbone; backbone containing olefin; aminosulfonate backbone; methylene imino and methylene hydrazine backbone; sulfonate and sulfonamide backbone; amide backbone; and N, O, S and CH with mixing 2 Other skeletons of components.

[0054] Nucleic acid can include nucleic acid mimics.Term " mimics " can be intended to include such polynucleotide, wherein only furanose ring or furanose ring and internucleotide linkage are replaced by non-furanose group, and only the replacement of furanose ring can also be referred to as sugar substitute.Heterocyclic base part or the heterocyclic base part of modification can be kept for hybridization with suitable target nucleic acid.A kind of such nucleic acid can be peptide nucleic acid (PNA).In PNA, the sugar backbone of polynucleotide can be replaced by containing amide backbone, specifically aminoethylglycine backbone.Nucleotide can be retained and directly or indirectly bonded to the aza nitrogen atom of the amide part of backbone.The backbone in PNA compound can comprise the aminoethylglycine unit of two or more connections that give PNA containing amide backbone.Heterocyclic base part can directly or indirectly bond to the aza nitrogen atom of the amide part of this backbone.

[0055] Nucleic acid can comprise morpholino backbone structure.For example, nucleic acid can comprise 6 yuan of morpholino rings to replace ribose ring.In some of these embodiments, diaminophosphoroester or other non-phosphodiester internucleoside linkage can replace phosphodiester bond.

[0056] Nucleic acid can comprise connected morpholino units (e.g., morpholino nucleic acids) having heterocyclic bases connected to morpholino rings. Linking groups can connect morpholino monomeric units in morpholino nucleic acids. Oligomeric compounds based on nonionic morpholinos can have less desirable interactions with cellular proteins. Polynucleotides based on morpholinos can be nonionic mimics of nucleic acids. Various compounds within morpholino species can be connected using different linking groups. Another class of polynucleotide mimics can be referred to as cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in nucleic acid molecules can be replaced by cyclohexenyl rings. Phosphoramidite monomers protected by CeNA DMT can be prepared and used for oligomeric compound synthesis using phosphoramidite chemistry. CeNA monomers are incorporated into nucleic acid chains to increase the stability of DNA / RNA hybrids. CeNA oligoadenylic acid can form complexes with nucleic acid complements, and these complexes have stability similar to natural complexes. Another modification may include a locked nucleic acid (LNA) in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring, thereby forming a 2'-C, 4'-C-oxymethylene bond, thereby forming a bicyclic sugar moiety. The bond may be a methylene (-CH 2 ) group, wherein n is 1 or 2. LNA and LNA analogs can show high duplex thermal stability (Tm = +3 to +10° C.), 3′ exonucleolytic degradation stability and good solubility properties comparable to complementary nucleic acids.

[0057] Nucleic acids can also include modifications or substitutions of nucleobases (often referred to simply as "bases"). As used herein, "unmodified" or "natural" nucleobases can include purine bases (e.g., adenine (A) and guanine (G)), and pyrimidine bases (e.g., thymine (T), cytosine (C), and uracil (U)). Modified nucleobases can include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo Uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-sulfhydryl, 8-sulfanyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo specifically 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-aminoadenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, and 3-deazaguanine and 3-deazaadenine. Modified nucleobases may include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido (5,4-b) (1,4) benzoxazin-2 (3H) -one), phenothiazine cytidine (1H-pyrimido (5,4-b) (1,4) benzothiazin-2 (3H) -one), G-clamps such as substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido (5,4-(b) (1,4) benzoxazin-2 (3H) -one), phenothiazine cytidine (1H-pyrimido (5,4-b) (1,4) benzothiazin-2 (3H) -one), The cytidines include 1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one, a G clamp ring such as a substituted phenoxazine cytidine (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one), a carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), a pyridoindole cytidine (H-pyrido(3',2':4,5)pyrrolo[2,3-d]pyrimidin-2-one).

[0058] As used herein, the term "sample" has its customary and ordinary meaning in the art in view of this specification. It may refer to a composition comprising a target. Samples suitable for analysis by the disclosed methods, devices and systems include cells, tissues, organs or organisms. In some embodiments, the sample includes a single cell. In some embodiments, the sample comprises, consists essentially of, or consists of at least 100,000, 200,000, 300,000, 500,000, 800,000 or 1,000,000 single cells.

[0059] As used herein, the term "sampling device" or "device" may refer to a device that can obtain a sample slice and / or place the slice on a substrate. The sample device may refer to, for example, a fluorescence activated cell sorter (FACS), a cell sorter, a biopsy needle, a biopsy device, a tissue slice device, a microfluidic device, a blade grid and / or a slicer.

[0060] As used herein, in view of this specification, the term "solid carrier" has its usual and common meaning in the art. It can refer to a discrete solid or semi-solid surface to which a plurality of barcodes (e.g., random barcodes) can be connected. Solid supports can encompass any type of solid, porous or hollow spheres, balls, bearings, cylinders or other similar configurations consisting of plastic, ceramic, metal or polymeric materials (e.g., hydrogels) on which nucleic acids can be fixed (e.g., covalently or non-covalently). Solid supports can include discrete particles, which can be spherical (e.g., microspheres) or have non-spherical or irregular shapes such as cubes, cuboids, cones, cylinders, cones, ellipsoids or discs, etc. The shape of a bead can be non-spherical. Multiple solid supports spaced apart in an array may not include a substrate. Solid supports can be used interchangeably with the term "beads". It is contemplated that wherever a solid support, such as a particle or surface, is described (e.g., if the barcode is immobilized on a solid support, particle, bead, etc.), another option is to distribute the solution into a distribution area so that the cell marker is associated one-to-one with the distribution area (and the cell marker is associated one-to-one with a single cell in the distribution area). Exemplary distribution areas may include drops (e.g., droplets), holes (e.g., microwells) that may be located on a substrate (e.g., a multi-well plate), and chambers in a fluid device (e.g., a microfluidic device). In some embodiments, the solutions described herein may be distributed in a distribution area containing no more than one cell. The distribution area may include at least one of: a droplet, a microwell, or a chamber of a fluid device such as a microfluidic device. The droplet may contain a hydrogel. The barcode may be immobilized on a substrate distribution area or may be free in a solution in the distribution area.

[0061] As used herein, the term "random barcode" may refer to a polynucleotide sequence comprising a tag of the present disclosure. A random barcode may be a polynucleotide sequence that can be used to randomly barcode. A random barcode may be used to quantify a target within a sample. A random barcode may be used to control errors that may occur after a tag is associated with a target. For example, a random barcode may be used to evaluate amplification or sequencing errors. A random barcode associated with a target may be referred to as a random barcode-target or a random barcode-tag-target.

[0062] As used herein, the term "gene-specific random barcode" may refer to a polynucleotide sequence comprising a tag and a gene-specific target binding region. A random barcode may be a polynucleotide sequence that can be used to randomly barcode. A random barcode may be used to quantify a target within a sample. A random barcode may be used to control errors that may occur after a tag is associated with a target. For example, a random barcode may be used to evaluate amplification or sequencing errors. A random barcode associated with a target may be referred to as a random barcode-target or a random barcode-tag-target.

[0063] As used herein, the term "stochastic barcoding" can refer to random labeling (e.g., barcoding) of nucleic acids. Stochastic barcoding can utilize a recursive Poisson strategy to correlate and quantify labels associated with a target. As used herein, the term "stochastic barcoding" can be used interchangeably with "random labeling."

[0064] As used herein, in view of this specification, the term "target" has its customary and common meaning in the art. It can refer to a component that can be associated with a barcode (e.g., a random barcode). Exemplary targets suitable for analysis by the present disclosure methods, devices, and systems include oligonucleotides, DNA, RNA, mRNA, microRNA, tRNA, etc. The target can be single-stranded or double-stranded. In some embodiments, the target can be a protein, peptide, or polypeptide. In some embodiments, the target is a lipid. As used herein, "target" can be used interchangeably with "species".

[0065] As used herein, in view of this specification, the term "reverse transcriptase" has its usual and common meaning in the art. It can refer to a group of enzymes with reverse transcriptase activity (i.e., catalyzing the synthesis of DNA by an RNA template). Generally speaking, such enzymes include but are not limited to retroviral reverse transcriptases, retrotransposon reverse transcriptases, reverse transcription plasmid reverse transcriptases, reverse transcriptase sub-reverse transcriptases, bacterial reverse transcriptases, reverse transcriptases derived from group II introns, and mutants, variants, or derivatives thereof. Non-retroviral reverse transcriptases include non-LTR retrotransposon reverse transcriptases, reverse transcription plasmid reverse transcriptases, reverse transcriptase sub-reverse transcriptases, and group II intron reverse transcriptases. Examples of group II intron reverse transcriptases include Lactococcus lactis LI.LtrB intron reverse transcriptase, Thermosynechococcuse longates TeI4c intron reverse transcriptase, or Geobacillus stearothermophilus GsI-IIC intron reverse transcriptase. Other types of reverse transcriptases can include many types of non-retroviral reverse transcriptases (i.e., transcripts, group II introns, and reverse transcription factors generated by diversity, etc.).

[0066] The terms "universal adapter primer," "universal primer adapter," or "universal adapter sequence" are used interchangeably and refer to a nucleotide sequence that can be used to hybridize a barcode (e.g., a random barcode) to generate a gene-specific barcode. The universal adapter sequence can be, for example, a known sequence that is common to all barcodes used in the methods disclosed herein. For example, when multiple targets are labeled using the methods disclosed herein, each of the target-specific sequences can be connected to the same universal adapter sequence. In some embodiments, more than one universal adapter sequence can be used in the methods disclosed herein. For example, when multiple targets are labeled using the methods disclosed herein, at least two of the target-specific sequences are connected to different universal adapter sequences. The universal adapter primer and its complement can be contained in two oligonucleotides, one of which contains a target-specific sequence and the other contains a barcode. For example, the universal adapter sequence can be an oligonucleotide portion that contains a target-specific sequence to generate a nucleotide sequence complementary to a target nucleic acid. A second oligonucleotide containing a barcode and a complementary sequence to the universal adapter sequence can hybridize with the nucleotide sequence and generate a target-specific barcode (e.g., a target-specific random barcode). In some embodiments, the universal adapter primer has a different sequence than the universal PCR primer used in the disclosed methods.

[0067] Barcode

[0068] Barcoding (such as random barcoding) has been described, for example, in US2015 / 0299784, WO 2015 / 031691, and Fu et al., Proc Natl Acad Sci USA 2011 May 31; 108(22):9026-31 (the contents of each of these publications are incorporated herein by reference in their entirety). In some embodiments, the barcodes disclosed herein can be random barcodes, which can refer to polynucleotide sequences that can be used to randomly label (e.g., barcode, tag) a target. A barcode can be referred to as a stochastic barcode if the ratio of the number of different barcode sequences of a stochastic barcode to the number of occurrences of any target to be labeled is or is about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or a number or range between any two of these values. The target can be an mRNA species comprising mRNA molecules having the same or nearly the same sequence. A barcode can be referred to as a stochastic barcode if the ratio of the number of different barcode sequences of a stochastic barcode to the number of occurrences of any target to be labeled is at least or at most 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100: 1. The barcode sequences of a stochastic barcode can be referred to as molecular markers.

[0069] A barcode, such as a random barcode, can include one or more tags. Exemplary tags can include a universal tag, a cell tag, a barcode sequence (e.g., a molecular tag), a sample tag, a plate tag, a spatial tag, and / or a pre-spatial tag. Figure 1 An exemplary barcode 104 with a spatial marker is shown. The barcode 104 can include a 5' amine that can connect the barcode to the solid support 105. The barcode can include a universal marker, a dimensional marker, a spatial marker, a cell marker, and / or a molecular marker. The barcode can include a universal marker, a cell marker, and a molecular marker. The barcode can include a universal marker, a spatial marker, a cell marker, and a molecular marker. The barcode can include a universal marker, a dimensional marker, a cell marker, and a molecular marker. The order of different markers (including but not limited to universal markers, dimensional markers, spatial markers, cell markers, and / or molecular markers) in the barcode can vary. For example, Figure 1As shown, the universal label can be the most 5' end label, and the molecular label can be the most 3' end label. Spatial label, dimensional label and cell label can be in any order. In certain embodiments, universal label, spatial label, dimensional label, cell label and molecular label are in any order. Barcode can include target binding region. Target binding region can interact with the target (for example, target nucleic acid, RNA, mRNA, DNA) in sample. For example, target binding region can include oligo (dT) sequence that can interact with poly (A) tail of mRNA. In some cases, the label of barcode (for example, universal label, dimensional label, spatial label, cell label and barcode sequence) can be separated by 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19 or 20 or more nucleotides.

[0070] Mark such as cell marker can further comprise the unique nucleic acid subsequence group of limiting length such as seven nucleotides (equal to the number of bits used in some Hamming error correction codes), and this nucleic acid subsequence group can be designed to provide error correction capability. The error correction subsequence group comprising seven nucleotide sequences can be designed to make any paired sequence combination in the group show the " genetic distance " (or mismatched base number) of limitation, and for example the error correction subsequence group can be designed to show the genetic distance of three nucleotides. In this case, the error correction sequence in the sequence data group of the target nucleic acid molecule (described more comprehensively below) of the inspection for mark can allow detection or correction amplification or sequencing error. In certain embodiments, the length of the nucleic acid subsequence for the generation of error correction code can vary, for example, they can be or be approximately 1,2,3,4,5,6,7,8,9,10,15,20,30,31,40,50 nucleotide lengths or any two numbers or scopes between these values. In certain embodiments, the nucleic acid subsequences of other lengths can be used to generate error correction code.

[0071] The barcode may include a target binding region. The target binding region may interact with a target in a sample. The target may be or include ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA each including a poly (A) tail, or any combination thereof. In some embodiments, multiple targets may include deoxyribonucleic acid (DNA).

[0072] In some embodiments, the target binding region may include an oligo(dT) sequence that can interact with the poly(A) tail of the mRNA. One or more markers of the barcode (e.g., universal markers, dimensional markers, spatial markers, cell markers, and barcode sequences (e.g., molecular markers)) may be separated from another or two remaining markers of the barcode by a spacer. The spacer may be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or more nucleotides. In some embodiments, no markers are separated by spacers in the markers of the barcode.

[0073] General Tags

[0074] The barcode may include one or more universal tags. In some embodiments, one or more universal tags may be the same for all barcodes in the barcode group connected to a specified solid support. In some embodiments, one or more universal tags may be the same for all barcodes connected to a plurality of beads. In some embodiments, the universal tag may include a nucleic acid sequence that can hybridize with a sequencing primer. A sequencing primer may be used to sequence the barcode comprising the universal tag. A sequencing primer (e.g., a universal sequencing primer) may include a sequencing primer associated with a high-throughput sequencing platform. In some embodiments, the universal tag may include a nucleic acid sequence that can hybridize with a PCR primer. In some embodiments, the universal tag may include a nucleic acid sequence that can hybridize with a sequencing primer and a PCR primer. The nucleic acid sequence that can hybridize with a sequencing primer or a PCR primer of the universal tag may be referred to as a primer binding site. The universal tag may include a sequence that can be used to initiate the transcription of a barcode. The universal tag may include a sequence that can be used to extend a barcode or a region within a barcode. The length of the universal tag can be or can be about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 nucleotides or a number or range between any two of these values. For example, the universal tag can contain at least about 10 nucleotides. The length of the universal tag can be at least or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides. In some embodiments, a cleavable linker or modified nucleotide can be part of the universal tag sequence to enable the barcode to be cleaved from the support.

[0075] Dimensional Tags

[0076] The barcode may include one or more dimension tags. In some embodiments, the dimension tag may include a nucleic acid sequence that provides information about the dimension in which the tag (e.g., random tag) appears. For example, the dimension tag may provide information about the time when the target is barcoded. The dimension tag may be associated with the barcoding (e.g., random barcoding) time of the sample. The dimension tag may be activated at the time of the tag. Different dimension tags may be activated at different times. The dimension tag provides information about the order in which the target, target group, and / or sample are barcoded. For example, a cell population may be barcoded during the G0 phase of the cell cycle. Cells may be pulsed again with a barcode (e.g., a random barcode) during the G1 phase of the cell cycle. Cells may be pulsed again with a barcode during the S phase of the cell cycle, and so on. The barcode under each pulse (e.g., each stage of the cell cycle) may include different dimension tags. In this way, the dimension tag provides information about which target is marked at which stage of the cell cycle. Dimension tags may interrogate many different biological periods. Exemplary biological phases may include, but are not limited to, cell cycle, transcription (e.g., transcription initiation), and transcript degradation. In another example, a sample (e.g., a cell, a cell population) may be labeled before and / or after treatment with a drug and / or therapy. Changes in the number of copies of different targets may indicate the response of the sample to a drug and / or therapy.

[0077] Dimensional markers can be activatable. Activatable dimensional markers can be activated at a specific time point. Activatable markers can be, for example, constitutively activated (for example, not closed). Activatable dimensional markers can be, for example, reversibly activated (for example, activatable dimensional markers can be opened and closed). Dimensional markers can, for example, reversibly activate at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 times or more. Dimensional markers can reversibly activate, for example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 times or more. In certain embodiments, dimensional markers can be activated with the following: fluorescence, daylight, chemical events (for example, cutting, the connection of another molecule, the addition of modification (for example, pegylation, sumoylation, acetylation, methylation, deacetylation, demethylation), photochemical events (for example, light cage shielding) and the introduction of non-natural nucleotides.

[0078] In some embodiments, the dimension label can be the same for all barcodes (e.g., random barcodes) attached to a given solid support (e.g., beads), but can be different for different solid supports (e.g., beads). In some embodiments, at least 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% of the barcodes on the same solid support can contain the same dimension label. In some embodiments, at least 60% of the barcodes on the same solid support can contain the same dimension label. In some embodiments, at least 95% of the barcodes on the same solid support can contain the same dimension label.

[0079] Up to 10 6 The length of the dimension marker can be or can be about 1,2,3,4,5,10,15,20,25,30,35,40,45,50 or the nucleotide of the number or range between any two values ​​in these values. The length of the dimension marker can be at least or at most 1,2,3,4,5,10,15,20,25,30,35,40,45,50,100,200 or 300 nucleotides. The dimension marker can include about 5 to about 200 nucleotides. The dimension marker can include about 10 to about 150 nucleotides. The length of the dimension marker can include about 20 to about 125 nucleotides.

[0080] Space Marking

[0081] The barcode may include one or more spatial markers. In some embodiments, the spatial marker may include a nucleic acid sequence that provides information about the spatial orientation of a target molecule associated with the barcode. The spatial marker may be associated with the coordinates of the sample. The coordinates may be fixed coordinates. For example, the coordinates may be fixed relative to a substrate. The spatial marker may be a reference two-dimensional or three-dimensional grid. The coordinates may be fixed relative to a landmark. The landmark may be identifiable in space. The landmark may be a structure that may be imaged. The landmark may be a biological structure, such as an anatomical landmark. The landmark may be a cell landmark, such as an organelle. The landmark may be a non-natural landmark such as a structure with an identifiable identifier such as color coding, barcode encoding, magnetic properties, fluorescent agent, radioactivity or a unique size or shape. The spatial marker may be associated with a physical segmentation (e.g., a hole, a container or a droplet). In some embodiments, a plurality of spatial markers are used together to encode one or more positions in space.

[0082] The spatial marker can be the same for all barcodes attached to a given solid support (e.g., a bead), but can be different for different solid supports (e.g., a bead). In some embodiments, the percentage of barcodes on the same solid support containing the same spatial marker can be or is about 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or range between any two of these values. In some embodiments, the percentage of barcodes on the same solid support containing the same spatial marker can be at least or at most 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or 100%. In some embodiments, at least 60% of the barcodes on the same solid support can contain the same spatial marker. In some embodiments, at least 95% of the barcodes on the same solid support can contain the same spatial marker.

[0083] Up to 10 6 The length of spatial marker can be or can be approximately 1,2,3,4,5,10,15,20,25,30,35,40,45,50 or the nucleotide of the number or scope between any two values ​​in these values.The length of spatial marker can be at least or at most 1,2,3,4,5,10,15,20,25,30,35,40,45,50,100,200 or 300 nucleotide.The spatial marker can comprise approximately 5 to approximately 200 nucleotides.The spatial marker can comprise approximately 10 to approximately 150 nucleotides.The length of spatial marker can comprise approximately 20 to approximately 125 nucleotides.

[0084] Cell labeling

[0085] Barcodes (e.g., random barcodes) may include one or more cell markers. In some embodiments, cell markers may include nucleic acid sequences that provide information for determining which target nucleic acid is derived from which cell. In some embodiments, cell markers are identical for all barcodes connected to a specified solid support (e.g., beads), but are different for different solid supports (e.g., beads). In some embodiments, the percentage of barcodes on the same solid support containing the same cell marker may be or be approximately 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or range between any two of these values. In some embodiments, the percentage of barcodes on the same solid support containing the same cell marker may be or be approximately 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or 100%. For example, at least 60% of the barcodes on the same solid support may include the same cell marker. As another example, at least 95% of the barcodes on the same solid support may include the same cell marker.

[0086] Up to 10 6 The length of cell labeling can be or can be approximately 1,2,3,4,5,10,15,20,25,30,35,40,45,50 or the nucleotide of the number or scope between any two values ​​in these values.The length of cell labeling can be at least or at most 1,2,3,4,5,10,15,20,25,30,35,40,45,50,100,200 or 300 nucleotides.For example, cell labeling can comprise approximately 5 to approximately 200 nucleotides.As another example, cell labeling can comprise approximately 10 to approximately 150 nucleotides.As another example, the length of cell labeling can comprise approximately 20 to approximately 125 nucleotides.

[0087] Barcode sequence

[0088] The barcode can include one or more barcode sequences. In some embodiments, the barcode sequence can include a nucleic acid sequence that provides identification information for a specific type of target nucleic acid species that hybridizes to the barcode. The barcode sequence can include a nucleic acid sequence that provides a counter (e.g., provides a rough approximation) for the specific number of occurrences of a target nucleic acid species that hybridizes to a barcode (e.g., a target binding region).

[0089] In some embodiments, a set of different barcode sequences are attached to a given solid support (e.g., a bead). In some embodiments, there may be at or about 10 2 , 10 3 , 104 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 A unique molecular marker sequence or a number or range between any two of these values. For example, the plurality of barcodes may include about 6561 barcode sequences having different sequences. As another example, the plurality of barcodes may include about 65536 barcode sequences having different sequences. In some embodiments, there may be at least or at most 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or 10 9 A unique barcode sequence. The unique molecular marker sequence can be attached to a given solid support (e.g., a bead). In some embodiments, the unique molecular marker sequence is partially or completely surrounded by a particle (e.g., a hydrogel bead).

[0090] In different implementations, the length of the barcode can be different. For example, the length of the barcode can be or can be about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 nucleotides, or a number or range between any two of these values. As another example, the length of the barcode can be at least or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides.

[0091] Molecular markers

[0092] A barcode (e.g., a random barcode) can include one or more molecular markers. A molecular marker can include a barcode sequence. In some embodiments, a molecular marker can include a nucleic acid sequence that provides identification information for a specific type of target nucleic acid species that hybridizes to a barcode. A molecular marker can include a nucleic acid sequence that provides a counter for a specific number of occurrences of a target nucleic acid species that hybridizes to a barcode (e.g., a target binding region).

[0093] In some embodiments, a set of different molecular markers are attached to a given solid support (e.g., beads). In some embodiments, there may be at or about 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 109 A unique molecular marker sequence or a number or range between any two of these values. For example, a plurality of barcodes may contain about 6561 molecular markers with different sequences. As another example, a plurality of barcodes may contain about 65536 molecular markers with different sequences. In some embodiments, there may be at least or at most 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or 10 9 A barcode with a unique molecular marker sequence can be attached to a given solid support (e.g., a bead).

[0094] For coding using multiple random barcodes (e.g., random barcoding), the ratio of the number of different molecular marker sequences to the number of occurrences of any target can be or is about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or a number or range between any two of these values. The target can be an mRNA species comprising mRNA molecules having the same or nearly identical sequence. In some embodiments, the ratio of the number of different molecular marker sequences to the number of occurrences of any target is at least or at most 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.

[0095] The length of a molecular marker can be or can be about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or a number or range of nucleotides between any two of these values. The length of a molecular marker can be at least or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides.

[0096] Target binding region

[0097] The barcode may comprise one or more target binding regions, such as capture probes. In some embodiments, the target binding region may hybridize with the target of interest. In some embodiments, the target binding region may comprise a nucleic acid sequence that specifically hybridizes with a target (e.g., a target nucleic acid, a target molecule, such as a cell nucleic acid to be analyzed), such as a specific gene sequence. In some embodiments, the target binding region may comprise a nucleic acid sequence that can be connected (hybridized) to a specific position of a specific target nucleic acid. In some embodiments, the target binding region may comprise a nucleic acid sequence that can specifically hybridize with a restriction endonuclease site overhang (e.g., an EcoRI sticky overhang). The barcode may then be connected to any nucleic acid molecule comprising a sequence complementary to a restriction endonuclease site overhang.

[0098] In some embodiments, the target binding region may include a non-specific target nucleic acid sequence. A non-specific target nucleic acid sequence may refer to a sequence that can bind to multiple target nucleic acids independently of the specific sequence of the target nucleic acid. For example, the target binding region may include a random polymer sequence, or an oligo (dT) sequence hybridized with a poly (A) tail on an mRNA molecule. The random polymer sequence may be, for example, a random dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nonamer, decamer or a higher polymer sequence with any length. In some embodiments, the target binding region is identical for all barcodes connected to a specified bead. In some embodiments, the target binding region for multiple barcodes connected to a specified bead may include two or more different target binding sequences. The length of the target binding region may be or may be approximately 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or a number or range of nucleotides between any two of these values. The target binding region may be up to about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides in length.

[0099] In some embodiments, the target binding region can include oligo(dT), which can hybridize to an mRNA comprising a polyadenylated end. The target binding region can be gene specific. For example, the target binding region can be configured to hybridize to a specific region of the target. In some embodiments, the target binding region does not include oligo(dT). The length of the target binding region can be or is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 27, 28, 29, 30 nucleotides or a number or range between any two of these values. The target binding region can be at least or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The target binding region can be from about 5-30 nucleotides in length. When a barcode comprises a gene-specific target binding region, the barcode can be referred to herein as a gene-specific barcode.

[0100] Orientation characteristics

[0101] Random barcodes (e.g., random barcodes) can include one or more orientation properties that can be used to orient (e.g., align) the barcodes. The barcodes can include a portion for isoelectric focusing. Different barcodes can include different isoelectric focusing points. When these barcodes are introduced into a sample, the sample can be subjected to isoelectric focusing so that the barcodes are oriented in a known manner. In this way, the orientation properties can be used to develop a known spectrum of barcodes in the sample. Exemplary orientation properties can include electrophoretic mobility (e.g., based on the size of the barcode), isoelectric point, spin, conductivity, and / or self-assembly. For example, a barcode with a self-assembly orientation property can self-assemble into a specific orientation (e.g., a nucleic acid nanostructure) after activation.

[0102] Affinity characteristics

[0103] Barcodes (e.g., random barcodes) may include one or more affinity properties. For example, a spatial tag may include an affinity property. Affinity properties may include chemical and / or biological moieties that may facilitate binding of the barcode to another entity (e.g., a cell receptor). For example, affinity properties may include antibodies, such as antibodies that are specific to a particular moiety (e.g., a receptor) on a sample. In some embodiments, antibodies may guide the barcode to a particular cell type or molecule. Targets at and / or near a particular cell type or molecule may be labeled (e.g., randomly labeled). In some embodiments, affinity properties may also provide spatial information in addition to the nucleotide sequence of the spatial tag, because antibodies may guide the barcode to a particular location. The antibody may be a therapeutic antibody, such as a monoclonal antibody or a polyclonal antibody. The antibody may be humanized or chimeric. The antibody may be a naked antibody or a fusion antibody.

[0104] Antibody can refer to a full-length (ie, naturally occurring or formed by normal immunoglobulin gene fragment recombination processes) immunoglobulin molecule (eg, IgG antibody) or an immunologically active (ie, specifically binding) portion of an immunoglobulin molecule, such as an antibody fragment.

[0105] The antibody fragment can be a part of an antibody, such as F(ab')2, Fab', Fab, Fv, sFv, etc. In some embodiments, the antibody fragment can bind to the same antigen identified by the full-length antibody. The antibody fragment can include a separated fragment consisting of the variable region of the antibody, such as an "Fv" fragment consisting of the variable region of the heavy chain and the light chain, and a recombinant single-chain polypeptide molecule in which the light chain variable region and the heavy chain variable region are connected by a peptide linker ("scFv protein"). Exemplary antibodies can include, but are not limited to, antibodies for cancer cells, antibodies for viruses, antibodies bound to cell surface receptors (CD8, CD34, CD45), and therapeutic antibodies.

[0106] Universal adapter primer

[0107] The barcode can comprise one or more universal adapter primers. For example, a gene-specific barcode, such as a gene-specific random barcode, can comprise a universal adapter primer. A universal adapter primer can refer to a nucleotide sequence that is universal across all barcodes. A universal adapter primer can be used to construct a gene-specific barcode. A universal adapter primer can be or is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 2627, 28, 29, 30 nucleotides or a value or range of nucleotides between any two of these values. The length of the universal adapter primer can be at least or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides. The length of the universal adapter primer can be from 5-30 nucleotides.

[0108] Connectors

[0109] When the barcode comprises more than one type of marker (e.g., more than one cell marker or more than one barcode sequence, such as a molecular marker), the marker can be interspersed with a linker marker sequence. The length of the linker marker sequence can be at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides. The length of the linker marker sequence can be up to about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides. In some cases, the length of the linker marker sequence is 12 nucleotides. The linker marker sequence can be used to facilitate the synthesis of the barcode. The linker marker can include an error correction code (e.g., a Hamming code).

[0110] Solid support

[0111] In some embodiments, the barcodes disclosed herein, such as random barcodes, can be associated with a solid support. The solid support can be, for example, a synthetic particle. In some embodiments, some or all barcode sequences, such as molecular markers of random barcodes (e.g., first multiple barcode sequences) in multiple barcodes (e.g., first multiple barcodes) on a solid support differ by at least one nucleotide. The cell markers of the barcodes on the same solid support can be the same. The cell markers of the barcodes on different solid supports can differ by at least one nucleotide. For example, the first cell marker of the first multiple barcodes on the first solid support can have the same sequence, and the second cell marker of the second multiple barcodes on the second solid support can have the same sequence. The first cell marker of the first multiple barcodes on the first solid support and the second cell marker of the second multiple barcodes on the second solid support can differ by at least one nucleotide. The cell marker can be, for example, about 5-20 nucleotides long. The barcode sequence can be, for example, about 5-20 nucleotides long. The synthetic particle can be, for example, a bead.

[0112] The beads can be, for example, silica beads, controlled pore glass beads, magnetic beads, Dynabeads, cross-linked dextran / cross-linked agarose beads, cellulose beads, polystyrene beads, or any combination thereof. The beads can comprise materials such as polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic, ceramic, plastic, glass, methylstyrene, acrylic polymers, titanium, latex, cross-linked agarose, cellulose, nylon, silicone, or any combination thereof.

[0113] In some embodiments, the beads can be polymer beads functionalized with barcodes or random barcodes, such as deformable beads or gel beads (e.g., gel beads from 10X Genomics (San Francisco, CA)). In some embodiments, the gel beads can comprise a polymer-based gel. The gel beads can be produced, for example, by encapsulating one or more polymer precursors into droplets. Gel beads can be produced when the polymer precursors are exposed to an accelerator, such as tetramethylethylenediamine (TEMED).

[0114] In some embodiments, the particles can be destructible (e.g., soluble, degradable). For example, the polymer beads can dissolve, melt, or degrade, for example, under desired conditions. The desired conditions can include environmental conditions. The desired conditions can cause the polymer beads to dissolve, melt, or degrade in a controlled manner. The gel beads can dissolve, melt, or degrade due to chemical stimulation, physical stimulation, biological stimulation, thermal stimulation, magnetic stimulation, electrical stimulation, light stimulation, or any combination thereof.

[0115] Analytes and / or reagents (e.g., oligonucleotide barcodes) can be coupled / immobilized, for example, on the inner surface of gel beads (e.g., by diffusion of the oligonucleotide barcodes and / or materials used to generate the oligonucleotide barcodes into the inner space) and / or on the outer surface of the gel beads or any other microcapsules described herein. Coupling / immobilization can be performed by any form of chemical bonding (e.g., covalent bonds, ionic bonds) or physical phenomena (e.g., van der Waals forces, dipole-dipole interactions, etc.). In some embodiments, the coupling / immobilization of reagents to gel beads or any other microcapsules described herein can be reversible, for example, via an unstable portion (e.g., via a chemical crosslinker including a chemical crosslinker described herein). After applying a stimulus, the unstable portion can be cleaved and release the immobilized reagent. In some embodiments, the unstable portion is a disulfide bond. For example, in the case where the oligonucleotide barcode is fixed to the gel beads by a disulfide bond, exposing the disulfide bond to a reducing agent can cleave the disulfide bond and cause the oligonucleotide barcode to detach from the beads. The labile moiety can be included as part of a gel bead or microcapsule, as part of a chemical linker that connects a reagent or analyte to a gel bead or microcapsule, and / or as part of a reagent or analyte. In some embodiments, at least one barcode in the plurality of barcodes can be immobilized on a particle, partially immobilized on a particle, enclosed in a particle, partially enclosed in a particle, or any combination thereof.

[0116] In some embodiments, the gel beads may include a plurality of different polymers, including but not limited to: polymers, thermosensitive polymers, photosensitive polymers, magnetic polymers, pH-sensitive polymers, salt-sensitive polymers, chemically sensitive polymers, polyelectrolytes, polysaccharides, peptides, proteins and / or plastics. The polymers may include but are not limited to the following materials, such as poly(N-isopropylacrylamide) (PNIPAAm), poly(styrenesulfonate) (PSS), poly(allylamine) (PAAm), poly(acrylic acid) (PAA), poly(ethyleneimine) (PEI), poly(diallyldimethylammonium chloride) (PDADMAC), poly(pyrrole) (PPy), poly(vinylpyrrolidone) (PVPON), poly(vinylpyridine) (PVP), poly(methacrylic acid) (PMAA), poly(methyl methacrylate) (PMMA), polystyrene (PS), poly(tetrahydrofuran) (PTHF), poly(o-phthalaldehyde) (PTHF), poly(hexylviologen) (PHV), poly(L-lysine) (PLL), poly(L-arginine) (PARG), poly(lactic-co-glycolic acid) (PLGA).

[0117] A variety of chemical stimuli can be used to trigger the destruction, dissolution or degradation of beads. Examples of these chemical changes can include, but are not limited to, pH-mediated changes in the bead wall, disintegration of the bead wall by chemical cleavage of crosslinks, triggering bead wall depolymerization and bead wall conversion reactions. Volume changes can also be used to trigger bead destruction.

[0118] Volumetric or physical changes in microcapsules by various stimuli also have many advantages in designing capsules that release agents. Volumetric or physical changes occur on a macroscopic scale, where bead rupture is the result of mechanical physical forces caused by the stimulus. These processes can include, but are not limited to, pressure-induced rupture, bead wall melting, or changes in the porosity of the bead wall.

[0119] Biostimulation can also be used to trigger the destruction, dissolution or degradation of beads. Generally, biotriggers are similar to chemical triggers, but many examples use biomolecules or molecules commonly found in biological systems, such as enzymes, peptides, sugars, fatty acids, nucleic acids, etc. For example, beads can include polymers with peptide crosslinks that are sensitive to cleavage by specific proteases. More specifically, one example can include microcapsules containing GFLGK peptide crosslinks. Upon addition of a biotrigger such as the protease cathepsin B, the peptide crosslinks of the shell pores are cleaved and the contents of the beads are released. In other cases, the protease can be thermally activated. In another example, the beads include a shell wall comprising cellulose. The addition of the hydrolase chitosan is a biotrigger for cleavage of cellulose bonds, depolymerization of the shell wall, and release of its internal contents.

[0120] The beads can also be induced to release their contents upon application of a thermal stimulus. Temperature changes can cause a variety of changes to occur in the beads. Thermal changes can cause the beads to melt, causing the bead wall to disintegrate. In other cases, heat can increase the internal pressure of components within the bead, causing the bead to rupture or explode. In other cases, heat can transform the bead into a shrunken, dehydrated state. Heat can also act on thermosensitive polymers within the bead wall, causing the bead to rupture.

[0121] Inclusion of magnetic nanoparticles into the bead wall of the microcapsule can allow for triggered rupture of the beads and for directing the beads into an array. For any purpose, the device of the present disclosure may include magnetic beads. In one example, Fe 3 O 4 Incorporation of nanoparticles into the polyelectrolyte containing beads triggers disruption.

[0122] Beads can also be disrupted, dissolved, or degraded due to electrical stimulation. Similar to the magnetic particles described in the previous section, electrically sensitive beads can simultaneously trigger bead rupture and other functions, such as alignment in an electric field, conductivity, or redox reactions. In one example, beads containing electrosensitive materials are aligned in an electric field so that the release of internal agents can be controlled. In other examples, the electric field can induce redox reactions within the bead wall itself, which can increase porosity.

[0123] Light stimulation can also be used to disrupt the beads. Many light triggers are possible and can include systems using various molecules such as nanoparticles and chromophores that can absorb photons of a specific wavelength range. For example, metal oxide coatings can be used as capsule triggers. 2 UV irradiation of polyelectrolyte capsules can cause the bead wall to disintegrate. In yet another example, a photo-switchable material such as an azobenzene group can be incorporated into the bead wall. Upon application of UV or visible light, such chemicals undergo a reversible cis-to-trans isomerization upon absorption of photons. In this regard, the introduction of a photon switch results in the bead wall either disintegrating or becoming more porous upon application of a light trigger.

[0124] For example, in Figure 2 In the non-limiting example of barcoding (e.g., random barcoding) shown in FIG, after introducing cells such as single cells into a plurality of microwells of a microwell array at block 208, beads can be introduced into a plurality of microwells of a microwell array at block 212. Each microwell can contain one bead. The beads can contain a plurality of barcodes. The barcodes can contain a 5' amine region attached to the beads. The barcodes can contain a universal tag, a barcode sequence (e.g., a molecular tag), a target binding region, or any combination thereof.

[0125] The barcodes disclosed herein can be associated (e.g., connected) with a solid support (e.g., a bead). The barcodes associated with the solid support can each include a barcode sequence selected from a group of at least 100 or 1000 barcode sequences having a unique sequence. In some embodiments, different barcodes associated with the solid support can include barcodes with different sequences. In some embodiments, a certain percentage of the barcodes associated with the solid support include the same cell marker. For example, the percentage can be or is about 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100% or a number or range between any two of these values. As another example, the percentage can be at least or at most 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99% or 100%. In some embodiments, the barcodes associated with the solid support can have the same cell marker. The barcodes associated with different solid supports can have different cell markers selected from a group comprising at least 100 or 1000 cell markers having unique sequences.

[0126] The barcodes disclosed herein can be associated (e.g., connected) with a solid support (e.g., a bead). In some embodiments, barcoding of multiple targets in a sample can be performed by a solid support comprising multiple synthetic particles associated with multiple barcodes. In some embodiments, a solid support can include multiple synthetic particles associated with multiple random barcodes. The difference in the spatial labeling of multiple barcodes on different solid supports can be at least one nucleotide. The solid support can, for example, contain multiple barcodes in two or three dimensions. The synthetic particles can be beads. The beads can be silica beads, controlled pore glass beads, magnetic beads, Dynabeads, cross-linked dextran / cross-linked agarose beads, cellulose beads, polystyrene beads, or any combination thereof. The solid support can include a polymer, a matrix, a hydrogel, a needle array device, an antibody, or any combination thereof. In some embodiments, the solid support can be free-floating. In some embodiments, the solid support can be embedded in a semi-solid or solid array. The barcode may not be associated with the solid support. The barcode can be a single nucleotide. The barcode can be associated with a substrate.

[0127] As used herein, the terms "tethered," "attached," and "fixed" are used interchangeably and may refer to covalent or non-covalent means for attaching a barcode to a solid support. Any of a number of different solid supports may be used as a solid support for attaching pre-synthesized barcodes or for in situ solid phase synthesis of barcodes.

[0128] In some embodiments, the solid support is a bead. The bead can encompass one or more types of solid, porous or hollow spheres, balls, bearings, cylinders, or other similar configurations on which nucleic acids can be fixed (e.g., covalently or non-covalently). The bead can be, for example, composed of plastic, ceramic, metal, polymeric material, or any combination thereof. The bead can be or include discrete particles that are spherical (e.g., microspheres) or have a non-spherical or irregular shape such as a cube, a cuboid, a cone, a cylinder, a cone, an ellipse, or a disc, etc. In some embodiments, the bead can be a non-spherical shape.

[0129] The beads may include a variety of materials, including, but not limited to, paramagnetic materials (such as magnesium, molybdenum, lithium, and tantalum), superparamagnetic materials (such as ferrite (Fe 3 O 4 ; magnetite) nanoparticles), ferromagnetic materials (e.g., iron, nickel, cobalt, some alloys thereof, and some rare earth metal compounds), ceramics, plastics, glass, polystyrene, silica, methylstyrene, acrylic polymers, titanium, latex, agarose gel, agarose, hydrogels, polymers, cellulose, nylon, or any combination thereof.

[0130] In some embodiments, the beads (eg, beads to which labels are attached) are hydrogel beads. In some embodiments, the beads comprise a hydrogel.

[0131] Some embodiments disclosed herein include one or more particles (e.g., beads). Each particle can include multiple oligonucleotides (e.g., barcodes). Each of the multiple oligonucleotides can include a barcode sequence (e.g., a molecular marker sequence), a cell marker, and a target binding region (e.g., an oligo (dT) sequence, a gene-specific sequence, a random polymer, or a combination thereof). The cell marker sequence of each of the multiple oligonucleotides can be the same. The cell marker sequences of the oligonucleotides on different particles can be different, so that the oligonucleotides on different particles can be identified. In different implementations, the number of different cell marker sequences can be different. In some embodiments, the number of cell marker sequences can be or is about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 10 ... 6 , 10 7 , 10 8 , 10 9 , a number or range between any two of these values, or greater. In some embodiments, the number of cell marker sequences can be at least or at most 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 10 ... 6 , 10 7 , 10 8 or 10 9In some embodiments, no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more of the plurality of particles include oligonucleotides having the same cell sequence. In some embodiments, the plurality of particles including oligonucleotides having the same cell sequence may be at most 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or more. In some embodiments, no particles in the plurality of particles have the same cell marker sequence.

[0132] The plurality of oligonucleotides on each particle can comprise different barcode sequences (e.g., molecular markers). In some embodiments, the number of barcode sequences can be or is about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 10 ... 6 , 10 7 , 10 8 , 10 9 , or a number or range between any two of these values. In some embodiments, the number of barcode sequences can be at least or at most 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 10 ... 6 , 10 7 , 10 8 or 10 9For example, at least 100 of the plurality of oligonucleotides comprise a different barcode sequence. As another example, in a single particle, at least 100, 500, 1000, 5000, 10000, 15000, 20000, 50000, a number or range between any two of these values, or more of the plurality of oligonucleotides comprise a different barcode sequence. Some embodiments provide a plurality of particles comprising a barcode. In some embodiments, the ratio of occurrences (or copies or number) of the target to be labeled to different barcode sequences can be at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or more. In some embodiments, each of the plurality of oligonucleotides further comprises a sample label, a universal label, or both. The particle can be, for example, a nanoparticle or a microparticle.

[0133] The size of the beads can vary. For example, the diameter of the beads can be in the range of 0.1 micrometers to 50 micrometers. In some embodiments, the diameter of the beads can be or is about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 micrometers, or a number or range between any two of these values.

[0134] The diameter of the beads can be related to the diameter of the holes of the substrate. In some embodiments, the diameter of the beads can be longer or shorter than the diameter of the hole or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or a number or range between any two of these values. The diameter of the beads can be related to the diameter of the cell (e.g., a single cell trapped by the hole of the substrate). In some embodiments, for example, the diameter of the beads can be longer or shorter than the diameter of the hole by at least or at most 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The diameter of the beads can be related to the diameter of the cell (e.g., a single cell trapped by the hole of the substrate). In some embodiments, the diameter of the bead can be longer or shorter than the diameter of the cell by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, or a number or range between any two of these values. In some embodiments, for example, the diameter of the bead can be longer or shorter than the diameter of the cell by at least or at most 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, or 300%.

[0135] The beads can be attached to and / or embedded in a substrate. The beads can be attached to and / or embedded in a gel, hydrogel, polymer and / or matrix. The spatial position of the beads in a substrate (e.g., gel, matrix, scaffold or polymer) can be identified using spatial markers present on the barcode on the beads that can serve as positional addresses.

[0136] Examples of beads may include, but are not limited to, streptavidin beads, agarose beads, magnetic beads, microbeads, antibody-conjugated beads (e.g., anti-immunoglobulin microbeads), protein A-conjugated beads, protein G-conjugated beads, protein A / G-conjugated beads, protein L-conjugated beads, oligo(dT)-conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads, and BcMag TM Carboxyl-terminated magnetic beads.

[0137] The beads may be associated with (e.g., impregnated with) quantum dots or fluorescent dyes so that they fluoresce in a fluorescent optical channel or multiple optical channels. The beads may be associated with iron oxide or chromium oxide so that they are paramagnetic or ferromagnetic. The beads may be identifiable. For example, a camera may be used to image the beads. The beads may have a detectable code associated with the beads. For example, the beads may contain a barcode. The beads may change size, for example, due to swelling in an organic or inorganic solution. The beads may be hydrophobic. The beads may be hydrophilic. The beads may be biocompatible.

[0138] The solid support (e.g., bead) can be visualized. The solid support can include a visualization label (e.g., a fluorescent dye). The solid support (e.g., bead) can be etched with an identifier (e.g., a number). The identifier can be visualized by imaging the bead.

[0139] The solid support may comprise insoluble, semi-soluble or insoluble materials. When the solid support comprises a linker, scaffold, building block or other reactive moiety attached thereto it may be referred to as "functionalized", however, when the solid support has no such reactive moiety attached thereto it may be referred to as "non-functionalized". The solid support may be employed in the following forms: free in solution, such as in a microtiter well; in a flow-through form, such as in a column; or in a dipstick.

[0140] Solid supports can include membranes, paper, plastics, coated surfaces, flat surfaces, glass, slides, chips or any combination thereof. Solid supports can be in the form of resins, gels, microspheres or other geometric configurations. Solid supports can include silica chips, microparticles, nanoparticles, plates, arrays, capillaries, plate supports such as glass fiber filters, glass surfaces, metal surfaces (steel, gold, silver, aluminum, silicon and copper), glass supports, plastic supports, silicon supports, chips, filters, membranes, microplates, slides, plastic materials including porous plates or membranes (e.g., formed by polyethylene, polypropylene, polyamide, polyvinylidene fluoride), and / or wafers, combs, pins or pins (e.g., pin arrays suitable for combinatorial synthesis or analysis) or flat surfaces such as wafers (silicon wafers), depressions of wafers with or without a depression of a filter bottom or beads in an array of nanoliter holes.

[0141] The solid support may comprise a polymer matrix (eg, a gel, a hydrogel). The polymer matrix may be capable of penetrating intracellular spaces (eg, around organelles). The polymer matrix may be capable of being pumped throughout the circulatory system.

[0142] Substrates and microwell arrays

[0143] As used herein, a substrate may refer to the type of solid support. A substrate may refer to a solid support that may contain a barcode random barcode of the present disclosure. A substrate may, for example, contain a plurality of micropores. For example, a substrate may be a well array containing two or more micropores. In some embodiments, a micropore may include a small reaction chamber of a defined volume. In some embodiments, a micropore may trap one or more cells. In some embodiments, a micropore may only trap one cell. In some embodiments, a micropore may trap one or more solid supports. In some embodiments, a micropore may only trap one solid support. In some embodiments, a micropore traps a single cell and a single solid support (e.g., a bead). A micropore may contain a barcode reagent of the present disclosure.

[0144] Barcoding method

[0145] The present disclosure provides methods for estimating the number of different targets at different locations in a body sample (e.g., tissue, organ, tumor, cell). These methods may include placing a barcode (e.g., a random barcode) in close proximity to a sample, lysing a sample, associating different targets with a barcode, amplifying targets and / or digitally counting targets. The method may further include analyzing and / or visualizing information obtained from spatial markers on the barcode. In some embodiments, the method includes visualizing multiple targets in the sample. Mapping multiple targets to a spectrogram of the sample may include generating a two-dimensional spectrogram or a three-dimensional spectrogram of the sample. The two-dimensional spectrogram and the three-dimensional spectrogram may be generated before or after barcoding multiple targets in the sample (e.g., random barcoding). Visualizing multiple targets in the sample may include mapping multiple targets to a spectrogram (map) of the sample. Mapping multiple targets to a spectrogram of the sample may include generating a two-dimensional spectrogram or a three-dimensional spectrogram of the sample. The two-dimensional spectrogram and the three-dimensional spectrogram may be generated before or after barcoding multiple targets in the sample. In some embodiments, the two-dimensional spectrogram and the three-dimensional spectrogram may be generated before the lysing sample. Lysing the sample before or after generating the two-dimensional spectrum or the three-dimensional spectrum may include heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.

[0146] In some embodiments, barcoding the plurality of targets comprises hybridizing the plurality of barcodes to the plurality of targets to generate barcoded targets (e.g., randomly barcoded targets). Barcoding the plurality of targets can comprise generating an indexed library of barcoded targets. Generating an indexed library of barcoded targets can be performed using a solid support comprising a plurality of barcodes (e.g., random barcodes).

[0147] Bring the sample and barcode into contact

[0148] The present disclosure provides methods for contacting a sample (e.g., a cell) with a substrate of the present disclosure. Samples including, for example, cells, organs, or tissue slices can be contacted with a barcode (e.g., a random barcode). Cells can be contacted, for example, by gravity flow, where the cells can settle and produce a monolayer. The sample can be a tissue slice. The slice can be placed on a substrate. The sample can be one-dimensional (e.g., forming a flat surface). The sample (e.g., a cell) can be spread on a substrate, for example, by growing / culturing the cells on a substrate.

[0149] When the barcode is in close proximity to the target, the target can hybridize to the barcode. The barcode can be non-consumably contacted so that each different target can be associated with a different barcode of the present disclosure. To ensure effective association between the target and the barcode, the target can be cross-linked to the barcode.

[0150] Cell lysis

[0151] After distributing cells and barcodes, cells can be lysed to release target molecules. Cell lysis can be accomplished in any of a variety of ways, such as by chemical or biochemical means, by osmotic shock or by thermal lysis, mechanical lysis or light lysis. Cells can be lysed by adding the following: cell lysis buffer containing detergents (such as SDS, lithium dodecyl sulfate, Triton X-100, Tween-20 or NP-40), organic solvents (such as methanol or acetone) or digestive enzymes (such as proteinase K, pepsin or trypsin) or any combination thereof. In order to increase the association of the target and the barcode, the diffusion rate of the target molecule can be changed by, for example, lowering the temperature and / or increasing the viscosity of the lysate.

[0152] In certain embodiments, the sample can be lysed using filter paper. The filter paper can be soaked with a lysis buffer on the filter paper. The filter paper can be applied to the sample under pressure that can contribute to the lysis of the sample and the hybridization of the target of the sample with the substrate.

[0153] In some embodiments, lysis can be performed by mechanical lysis, thermal lysis, optical lysis and / or chemical lysis. Chemical lysis can include the use of digestive enzymes such as proteinase K, pepsin and trypsin. Cleavage can be performed by adding lysis buffer to the substrate. The lysis buffer can include Tris HCl. The lysis buffer can include at least about 0.01M, 0.05M, 0.1M, 0.5M or 1M or more Tris HCl. The lysis buffer can include up to about 0.01M, 0.05M, 0.1M, 0.5M or 1M or more Tris HCL. The lysis buffer can include about 0.1M Tris HCl. The pH of the lysis buffer can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or higher. The pH of the lysis buffer can be up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or higher. In some embodiments, the pH of the lysis buffer is about 7.5. The lysis buffer can include salt (e.g., LiCl). The concentration of salt in the lysis buffer may be at least about 0.1M, 0.5M, or 1M, or higher. The concentration of salt in the lysis buffer may be up to about 0.1M, 0.5M, or 1M, or higher. In some embodiments, the concentration of salt in the lysis buffer is about 0.5M. The lysis buffer may contain a detergent (e.g., SDS, lithium dodecyl sulfate, triton X, Tween, NP-40). The concentration of detergent in the lysis buffer may be at least about 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, or 7% or higher. The concentration of detergent in the lysis buffer can be at most about 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6% or 7% or higher. In some embodiments, the concentration of detergent in the lysis buffer is about 1% lithium dodecyl sulfate. The time used in the lysis method can depend on the amount of detergent used. In some embodiments, the more detergent used, the less time required for lysis. The lysis buffer can contain a chelating agent (e.g., EDTA, EGTA). The concentration of chelating agent in the lysis buffer can be at least about 1, 5, 10, 15, 20, 25 or 30mM or higher. The concentration of chelating agent in the lysis buffer can be at most about 1, 5, 10, 15, 20, 25 or 30mM or higher. In some embodiments, the concentration of chelating agent in the lysis buffer is about 10mM. The lysis buffer may contain a reducing agent (e.g., β-mercaptoethanol, DTT). The concentration of the reducing agent in the lysis buffer may be at least about 1, 5, 10, 15, or 20 mM or more. The concentration of the reducing agent in the lysis buffer may be at most about 1, 5, 10, 15, or 20 mM or more.In some embodiments, the concentration of the reducing agent in the lysis buffer is about 5 mM. In some embodiments, the lysis buffer can comprise about 0.1 M TrisHCl, about pH 7.5, about 0.5 M LiCl, about 1% lithium dodecyl sulfate, about 10 mM EDTA, and about 5 mM DTT.

[0154] Lysis can be performed at a temperature of about 4°C, 10°C, 15°C, 20°C, 25°C or 30°C. Lysis can be performed for about 1, 5, 10, 15 or 20 minutes or more. Lysed cells can contain at least about 100,000, 200,000, 300,000, 400,000, 500,000, 600,000 or 700,000 or more target nucleic acid molecules. Lysed cells can contain up to about 100,000, 200,000, 300,000, 400,000, 500,000, 600,000 or 700,000 or more target nucleic acid molecules.

[0155] Barcodes are attached to target nucleic acid molecules

[0156] After the cells are lysed and the nucleic acid molecules are released therefrom, the nucleic acid molecules can be randomly associated with the barcodes of the co-located solid supports. The association can include hybridization of the target recognition region of the barcode with the complementary portion of the target nucleic acid molecule (e.g., the oligo(dT) of the barcode can be associated with the poly(A) tail of the target). The assay conditions for hybridization (e.g., buffer pH, ionic strength, temperature, etc.) can be selected to promote the formation of a specific stability hybrid. In some embodiments, the nucleic acid molecules released from the lysed cells can be associated with multiple probes on the substrate (e.g., hybridized with probes on the substrate). When the probe contains oligo(dT), the mRNA molecule can hybridize with the probe and be reverse transcribed. The oligo(dT) portion of the oligonucleotide can serve as a primer for the first chain synthesis of a cDNA molecule. For example, in Figure 2 In the non-limiting example of a barcode shown in , the mRNA molecule can be hybridized to the barcode on the bead at block 216. For example, a single-stranded nucleotide fragment can be hybridized to the target binding region of the barcode.

[0157] The connection may further include connecting the target recognition region of the barcode to a portion of the target nucleic acid molecule. For example, the target binding region may include a nucleic acid sequence that can be specifically hybridized with a restriction site overhang (e.g., an EcoRI sticky end overhang). The assay procedure may further include treating the target nucleic acid with a restriction endonuclease (e.g., EcoRI) to produce a restriction site overhang. The barcode may then be connected to any nucleic acid molecule comprising a sequence complementary to the restriction site overhang. A ligase (e.g., T4 DNA ligase) may be used to join the two fragments.

[0158] For example, in Figure 2In the non-limiting example of the barcodes shown in , the labeled targets (e.g., target-barcode molecules) from multiple cells (or multiple samples) can then be combined, for example, into a tube at block 220. The labeled targets can be combined by, for example, recovering barcodes and / or beads attached to target-barcode molecules.

[0159] Retrieval of the solid support-based collection of linked target-barcode molecules can be achieved by using magnetic beads and an externally applied magnetic field. Once the target-barcode molecules have been combined, all further processing can be performed in a single reactor. Additional processing can include, for example, reverse transcription reactions, amplification reactions, cleavage reactions, dissociation reactions, and / or nucleic acid extension reactions. Additional processing reactions can be performed within the microwells, that is, without first combining labeled target nucleic acid molecules from multiple cells.

[0160] Reverse transcription

[0161] The present disclosure provides a method for producing a target-barcode conjugate using reverse transcription (e.g., in Figure 2 224 of the present invention). The target-barcode conjugate can include a complementary sequence of all or a portion of a barcode and a target nucleic acid (i.e., a barcoded cDNA molecule, such as a randomly barcoded cDNA molecule). Reverse transcription of the associated RNA molecule can occur by adding a reverse transcription primer and a reverse transcriptase. The reverse transcription primer can be an oligo(dT) primer, a random hexanucleotide primer, or a target-specific oligonucleotide primer. The oligo(dT) primer can be or can be about 12-18 nucleotides in length and binds to an endogenous poly(A) tail at the 3' end of a mammalian mRNA. The random hexanucleotide primer can bind to the mRNA at multiple complementary sites. The target-specific oligonucleotide primer typically selectively primes the mRNA of interest.

[0162] In certain embodiments, the reverse transcription of the RNA molecule of labeling can occur by adding a reverse transcription primer. In certain embodiments, the reverse transcription primer is an oligo (dT) primer, a random hexanucleotide primer or a target-specific oligonucleotide primer. Generally speaking, an oligo (dT) primer is a length of about 12-18 nucleotides and combines the endogenous poly (A) tail at the 3' end of mammalian mRNA. A random hexanucleotide primer can combine mRNA at multiple complementary sites. Target-specific oligonucleotide primers typically selectively trigger the mRNA of interest.

[0163] Reverse transcription can occur repeatedly to produce a plurality of labeled cDNA molecules. The method disclosed herein may include performing at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 reverse transcription reactions. The method may include performing at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 reverse transcription reactions.

[0164] Amplification

[0165] One or more nucleic acid amplification reactions can be performed (e.g., Figure 2 The amplification reaction may be performed in a multiplex circuit manner, wherein multiple target nucleic acid sequences are amplified simultaneously. The amplification reaction may be used to add sequencing adapters to the nucleic acid molecules. The amplification reaction may include amplifying at least a portion of the sample label (if present). The amplification reaction may include amplifying at least a portion of a cell label and / or a barcode sequence (e.g., a molecular marker). The amplification reaction may include amplifying at least a portion of a sample label, a cell label, a spatial label, a barcode sequence (e.g., a molecular marker), a target nucleic acid, or a combination thereof. The amplification reaction can include amplifying 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 100% of a plurality of nucleic acids, or a range or value between any two of these values. The method can further include performing one or more cDNA synthesis reactions to generate one or more cDNA copies of a target-barcode molecule comprising a sample marker, a cell marker, a spatial marker, and / or a barcode sequence (e.g., a molecular marker).

[0166] In some embodiments, amplification can be performed using polymerase chain reaction (PCR). As used herein, PCR can refer to a reaction for in vitro amplification of a specific DNA sequence by simultaneously extending the complementary strand of the DNA with primers. As used herein, PCR can encompass derivative forms of the reaction, including but not limited to RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplex PCR, digital PCR, and assembly PCR.

[0167] The amplification of the nucleic acid of labeling can include the method based on non-PCR.The example based on the method of non-PCR includes but is not limited to multiple displacement amplification (MDA), transcription-mediated amplification (TMA), amplification (NASBA) based on nucleic acid sequence, strand displacement amplification (SDA), real-time SDA, rolling circle amplification or ring-to-ring amplification.Other methods based on non-PCR include multiple cycles of DNA synthesis and transcription of RNA transcription amplification driven by RNA-dependent RNA polymerase or RNA-guided DNA synthesis and transcription for amplification of DNA or RNA targets, ligase chain reaction (LCR) and Qβ replicase (Qβ) methods, using palindromic probes, strand displacement amplification, using oligonucleotide-driven amplification of restriction endonucleases, wherein primers are hybridized with nucleic acid sequences and the amplification method in which the resulting duplex is cut before extension reaction and amplification, using strand displacement amplification of nucleic acid polymerase lacking 5' exonuclease activity, rolling circle amplification and branched extension amplification (RAM).In certain embodiments, amplification does not produce circularized transcripts.

[0168] In some embodiments, the method disclosed herein further includes performing a polymerase chain reaction on a labeled nucleic acid (e.g., labeled RNA, labeled DNA, labeled cDNA) to produce a labeled amplicon (e.g., a randomly labeled amplicon). The labeled amplicon can be a double-stranded molecule. The double-stranded molecule can include a double-stranded RNA molecule, a double-stranded DNA molecule, or an RNA molecule hybridized with a DNA molecule. One or both chains of the double-stranded molecule can contain a sample label, a spatial label, a cell label, and / or a barcode sequence (e.g., a molecular label). The labeled amplicon can be a single-stranded molecule. The single-stranded molecule can include DNA, RNA, or a combination thereof. The nucleic acid disclosed herein can include a synthetic or altered nucleic acid.

[0169] Amplification can include the use of one or more non-natural nucleotides. Non-natural nucleotides can include light instability or triggerable nucleotides. Examples of non-natural nucleotides can include but are not limited to peptide nucleic acids (PNA), morpholinos and locked nucleic acids (LNA) and glycol nucleic acids (GNA) and threose nucleic acids (TNA). Non-natural nucleotides can be added to one or more cycles of an amplified reaction. The interpolation of non-natural nucleotides can be used to identify the product of a specific cycle or time point in an amplified reaction.

[0170] Carrying out one or more amplification reactions can include using one or more primers.One or more primers can include, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 or more nucleotides.One or more primers can include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 or more nucleotides.One or more primers can include less than 12-15 nucleotides.One or more primers can anneal to at least a portion of a plurality of labeled targets (e.g., randomly labeled targets).One or more primers can anneal to 3' ends or 5' ends of a plurality of labeled targets.One or more primers can anneal to the internal region of a plurality of labeled targets. The internal region can be at least about 50, 100, 150, 200, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 650, 700, 750, 800, 850, 900 or 1000 nucleotides from the 3' end of a plurality of labeled targets. The one or more primers can include a set of fixed primers. The one or more primers can include at least one or more custom primers. The one or more primers may include at least one or more control primers.The one or more primers may include at least one or more gene-specific primers.

[0171] One or more primers may include universal primers. Universal primers may anneal to universal primer binding sites. One or more custom primers may anneal to a first sample marker, a second sample marker, a spatial marker, a cell marker, a barcode sequence (e.g., a molecular marker), a target, or any combination thereof. One or more primers may include universal primers and custom primers. Custom primers may be designed to amplify one or more targets. The target may include a subset of total nucleic acids in one or more samples. The target may include a subset of total labeled targets in one or more samples. One or more primers may include at least 96 or more custom primers. One or more primers may include at least 960 or more custom primers. One or more primers may include at least 9600 or more custom primers. One or more custom primers may anneal to two or more different labeled nucleic acids. Two or more different labeled nucleic acids may correspond to one or more genes.

[0172] Any amplification scheme can be used in the method of the present disclosure. For example, in one scheme, the first round of PCR can use gene-specific primers and primers for universal Illumina sequencing primer 1 sequence to amplify molecules attached to beads. The second round of PCR can use nested gene-specific primers flanking Illumina sequencing primer 2 sequence and primers for universal Illumina sequencing primer 1 sequence to amplify the first PCR product. The third round of PCR adds P5 and P7 and sample index to transfer the PCR product into the Illumina sequencing library. Sequencing using 150bp×2 sequencing can reveal cell markers and barcode sequences (e.g., molecular markers) on read 1, genes on read 2, and sample indexes on index 1 reads.

[0173] In some embodiments, chemical cutting can be used to remove nucleic acid from substrate. For example, chemical groups or modified bases present in nucleic acid can be used to facilitate its removal from solid support. For example, enzymes can be used to remove nucleic acid from substrate. For example, nucleic acid can be removed from substrate by restriction endonuclease digestion. For example, nucleic acid containing dUTP or ddUTP can be treated with uracil-d-glycosylase (UDG) to remove nucleic acid from substrate. For example, nucleic acid can be removed from substrate using enzymes such as base excision repair enzymes such as apurinic / apyrimidinic (AP) that perform nucleotide excision. In some embodiments, nucleic acid can be removed from substrate using photo-cleavable groups and light. In some embodiments, nucleic acid can be removed from substrate using a cleavable joint. For example, a cleavable joint can include at least one of biotin / avidin, biotin / streptavidin, biotin / neutravidin, Ig protein A, photolabile joints, acid or base labile joints or aptamers.

[0174] When the probe is gene-specific, the molecule can hybridize with the probe and be reverse transcribed and / or amplified. In some embodiments, after the nucleic acid has been synthesized (e.g., reverse transcribed), it can be synthesized. Amplification can be performed in a multiplex circuit manner, wherein multiple target nucleic acid sequences are amplified simultaneously. Amplification can add sequencing adapters to the nucleic acid.

[0175] In some embodiments, amplification can be performed on a substrate, for example, with bridge amplification. Homopolymer tailing can be performed on cDNA to generate compatible ends for bridge amplification using oligo (dT) probes on a substrate. In bridge amplification, the primer complementary to the 3' end of the template nucleic acid can be the first primer covalently connected to solid particles in each pair. When a sample containing template nucleic acid contacts the particle and performs a single thermal cycle, the template molecule can anneal to the first primer and extend the first primer in the forward direction to form a duplex molecule composed of the template molecule and the newly formed DNA complementary to the template by adding nucleotides. In the heating step of the next cycle, the duplex molecule can be denatured, so that the template molecule is released from the particle and leaves the complementary DNA chain connected to the particle by the first primer. In the annealing stage of the annealing and extension step performed subsequently, the complementary chain can be hybridized with the second primer, which is complementary to the segment of the complementary chain at the position removed from the first primer. This hybridization can make complementary chain form bridge between first primer and second primer, and this bridge is fixed to first primer by covalent bond and is fixed to second primer by hybridization.In the extension stage, can make second primer extend in reverse direction by adding nucleotide in same reaction mixture, thereby bridge is converted into double-stranded bridge.Then start next circulation, and can make double-stranded bridge denaturation to produce two stranded nucleic acid molecules, each nucleic acid molecule has an end that is connected to particle via first primer and second primer, and the other end of each nucleic acid molecule is unconnected.In the annealing and extension step of this second circulation, each chain can hybridize with previously unused other complementary primer on same particle to form new stranded bridge.Two kinds of previously unused primers of hybridization now extend so that two new bridges are converted into double-stranded bridge.

[0176] The amplification reaction can include amplifying at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or 100% of a plurality of nucleic acids.

[0177] The amplification of the nucleic acid of the mark can include a PCR-based method or a non-PCR-based method. The amplification of the nucleic acid of the mark can include the exponential amplification of the nucleic acid of the mark. The amplification of the nucleic acid of the mark can include the linear amplification of the nucleic acid of the mark. Amplification can be performed by polymerase chain reaction (PCR). PCR can refer to the reaction for in vitro amplification of a specific DNA sequence by extending the complementary strand of the DNA with primers at the same time. PCR can cover derivative forms of reactions, including but not limited to RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplex PCR, digital PCR, inhibition PCR, semi-inhibition PCR and assembly PCR.

[0178] In some embodiments, the amplification of the labeled nucleic acid includes a non-PCR-based method. Examples of non-PCR-based methods include, but are not limited to, multiple displacement amplification (MDA), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), chain displacement amplification (SDA), real-time SDA, rolling circle amplification, or loop-to-loop amplification. Other non-PCR-based methods include multiple cycles of RNA transcription amplification driven by a DNA-dependent RNA polymerase or RNA-guided DNA synthesis and transcription for amplification of DNA or RNA targets, ligase chain reaction (LCR), Qβ replicase (Qβ), using palindromic probes, chain displacement amplification, oligonucleotide-driven amplification using restriction endonucleases, wherein primers are hybridized to nucleic acid sequences and the resulting duplex is cut before extension reaction and amplification. Amplification methods, chain displacement amplification, rolling circle amplification, and / or branched extension amplification (RAM) using a nucleic acid polymerase lacking 5' exonuclease activity.

[0179] In certain embodiments, the method disclosed herein further includes performing a nested polymerase chain reaction on the amplified amplicon (e.g., target). The amplicon can be a double-stranded molecule. The double-stranded molecule can include a double-stranded RNA molecule, a double-stranded DNA molecule, or an RNA molecule hybridized with a DNA molecule. One or both chains of the double-stranded molecule can include a sample tag or a molecular identifier label. Alternatively, the amplicon can be a single-stranded molecule. The single-stranded molecule can include DNA, RNA, or a combination thereof. The nucleic acid described herein can include a synthetic or altered nucleic acid.

[0180] In some embodiments, the method includes repeatedly amplifying the labeled nucleic acid to produce a plurality of amplicons. The method disclosed herein may include performing at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amplification reactions. Alternatively, the method includes performing at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amplification reactions.

[0181] Amplification can further include adding one or more control nucleic acids to one or more samples comprising multiple nucleic acids. Amplification can further include adding one or more control nucleic acids to multiple nucleic acids. The control nucleic acids can include a control label.

[0182] Amplification can include the use of one or more non-natural nucleotides. Non-natural nucleotides can include light unstable and / or triggerable nucleotides. Examples of non-natural nucleotides include but are not limited to peptide nucleic acids (PNA), morpholinos and locked nucleic acids (LNA) and glycol nucleic acids (GNA) and threose nucleic acids (TNA). Non-natural nucleotides can be added to one or more cycles of an amplified reaction. The interpolation of non-natural nucleotides can be used to identify the product of a specific cycle or time point in an amplified reaction.

[0183] Carrying out one or more amplification reactions can include using one or more primers. One or more primers can include one or more oligonucleotides. One or more oligonucleotides can contain at least about 7-9 nucleotides. One or more oligonucleotides can contain less than 12-15 nucleotides. One or more primers can anneal to at least a portion of a plurality of labeled nucleic acids. One or more primers can anneal to the 3' end and / or the 5' end of a plurality of labeled nucleic acids. One or more primers can anneal to an internal region of a plurality of labeled nucleic acids. The inner region can be at least about 50, 100, 150, 200, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 650, 700, 750, 800, 850, 900 or 1000 nucleotides from the 3' end of the nucleic acid of multiple labels. One or more primers can include a set of fixed primers. One or more primers can include at least one or more custom primers. One or more primers may include at least one or more control primers. One or more primers may include at least one or more housekeeping gene primers. One or more primers may include universal primers. Universal primers may anneal to universal primer binding sites. One or more custom primers may anneal to the first sample label, the second sample label, a molecular identifier tag, a nucleic acid or its product. One or more primers may include universal primers and custom primers. Custom primers may be designed to amplify one or more target nucleic acids. Target nucleic acids may include a subset of total nucleic acids in one or more samples. In certain embodiments, primers are probes connected to an array of the present disclosure.

[0184] In some embodiments, barcoding (e.g., random barcoding) multiple targets in a sample also includes generating an index library of barcoded targets (e.g., randomly barcoded targets) or barcoded target fragments. The barcode sequences of different barcodes (e.g., molecular markers of different random barcodes) can be different from each other. Generating an index library of barcoded targets includes generating multiple indexed polynucleotides from multiple targets in a sample. For example, for an index library of barcoded targets comprising a first indexed target and a second indexed target, the difference between the marker region of the polynucleotide of the first index and the marker region of the polynucleotide of the second index can be, about, at least or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 nucleotides, or a number or range between any two of these values. In some embodiments, generating an index library of barcoded targets includes contacting a plurality of targets, such as mRNA molecules, with a plurality of oligonucleotides (comprising a poly(T) region and a tag region); and performing first strand synthesis using a reverse transcriptase to generate single-stranded labeled cDNA molecules, each cDNA molecule comprising a cDNA region and a tag region, wherein the plurality of targets comprises at least two mRNA molecules having different sequences and the plurality of oligonucleotides comprises at least two oligonucleotides having different sequences. Generating an index library of barcoded targets may further comprise amplifying the single-stranded labeled cDNA molecules to generate double-stranded labeled cDNA molecules; and performing nested PCR on the double-stranded labeled cDNA molecules to generate labeled amplicons. In some embodiments, the method may comprise generating adapter-labeled amplicons.

[0185] Barcoding (e.g., random barcoding) can use nucleic acid barcodes or tags to label individual nucleic acid (e.g., DNA or RNA) molecules. In some embodiments, when cDNA molecules are generated from mRNA, random barcoding involves adding DNA barcodes or tags to cDNA molecules. Nested PCR can be performed to minimize PCR amplification bias. Adapters can be added for sequencing using, for example, next generation sequencing (NGS). The sequencing results can be used to determine cell markers, molecular markers, and nucleotide fragment sequences of one or more copies of a target, such as in Figure 2 at box 232.

[0186] Figure 3is a schematic diagram showing a non-limiting exemplary process for generating an indexed library of barcoded targets (e.g., randomly barcoded targets) (e.g., barcoded mRNAs or fragments thereof). As shown in step 1, the reverse transcription process can encode each mRNA molecule with a unique molecular marker sequence, a cell marker sequence, and a universal PCR site. Specifically, by hybridizing (e.g., randomly hybridizing) a set of barcodes (e.g., random barcodes) 310 with a poly (A) tail region 308 of an RNA molecule 302, the RNA molecule 302 can be reverse transcribed to generate a labeled cDNA molecule 304 (including a cDNA region 306). Each of the barcodes 310 can include a target binding region, such as a poly (dT) region 312, a marker region 314 (e.g., a barcode sequence or molecule), and a universal PCR region 316.

[0187] In some embodiments, the cell marker sequence may comprise 3 to 20 nucleotides. In some embodiments, the molecular marker sequence may comprise 3 to 20 nucleotides. In some embodiments, each of the plurality of random barcodes further comprises one or more of a universal marker and a cell marker, wherein the universal marker is identical to the plurality of random barcodes on the solid support and the cell marker is identical to the plurality of random barcodes on the solid support. In some embodiments, the universal marker may comprise 3 to 20 nucleotides. In some embodiments, the cell marker comprises 3 to 20 nucleotides.

[0188] In some embodiments, the marker region 314 may include a barcode sequence or molecular marker 318 and a cell marker 320. In some embodiments, the marker region 314 may include one or more of a universal marker, a dimensional marker, and a cell marker. The length of the barcode sequence or molecular marker 318 may be, may be about, may be at least, or may be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a value or range of nucleotides between any of these values. The length of the cell marker 320 may be, may be about, may be at least, or may be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a value or range of nucleotides between any of these values. The length of the universal tag can be, can be about, can be at least or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or a value or range of nucleotides between any of these values. The universal tag can be the same for multiple random barcodes on the solid support and the cell tag can be the same for multiple random barcodes on the solid support. The length of the dimensional tag can be, can be about, can be at least, or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or a value or range of nucleotides between any of these values.

[0189] In some embodiments, the marker region 314 can include, include about, include at least or include at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or a number or range between any of these values, of different markers, such as barcode sequences or molecular markers 318 and cell markers 320. The length of each marker can be, can be about, can be at least or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range between any of these values, of nucleotides. The group of barcodes or random barcodes 310 may include, include about, include at least, or include at most 10, 20, 40, 50, 70, 80, 90, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 108 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 , 10 20 Or any value or range between these values ​​barcodes or random barcodes 310. And, the group of barcodes or random barcodes 310 can, for example, each contain a unique tag region 314. The labeled cDNA molecules 304 can be purified to remove excess barcodes or random barcodes 310. Purification can include Ampure bead purification.

[0190] As shown in step 2, the products from the reverse transcription process of step 1 can be combined into 1 tube and PCR amplified using the first PCR primer pool and the first universal PCR primer. The combination is possible due to the unique labeling region 314. Specifically, the labeled cDNA molecules 304 can be amplified to produce nested PCR labeled amplicons 322. The amplification can include multiplex PCR amplification. The amplification can include multiplex PCR amplification using 96 multiplex primers in a single reaction volume. In some embodiments, the multiplex PCR amplification can utilize, utilize about, utilize at least or utilize at most 10, 20, 40, 50, 70, 80, 90, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 , 10 20 Amplification may include using a first PCR primer pool 324 that includes custom primers 326A-C targeting a specific gene and a universal primer 328. Custom primers 326 may hybridize to a region within the cDNA portion 306' of the labeled cDNA molecule 304. Universal primers 328 may hybridize to universal PCR regions 316 of the labeled cDNA molecule 304.

[0191] like Figure 3As shown in step 3 of , the product of PCR amplification from step 2 can be amplified with a nested PCR primer library and a second universal PCR primer. Nested PCR can minimize PCR amplification deviation. Specifically, the amplicon 322 of the nested PCR marker can be further amplified by nested PCR. Nested PCR can include multiple PCR using a nested PCR primer pool 330 of nested PCR primers 332a-c and a second universal PCR primer 328' in a single reaction volume. The nested PCR primer pool 328 can include, include about, include at least or include at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or a numerical value or range between any of these values ​​of different nested PCR primers 330. Nested PCR primer 332 may contain adapter 334 and hybridize to a region within cDNA portion 306″ of labeled amplicon 322. Universal primer 328′ may contain adapter 336 and hybridize to universal PCR region 316 of labeled amplicon 322. Thus, step 3 produces adapter-tagged amplicon 338. In some embodiments, nested PCR primer 332 and second universal PCR primer 328′ may not contain adapters 334 and 336. Instead, adapters 334 and 336 may be ligated to the product of the nested PCR to produce adapter-tagged amplicon 338.

[0192] As shown in step 4, the PCR product from step 3 can be PCR amplified using library amplification primers for sequencing. Specifically, adapters 334 and 336 can be used to perform one or more additional assays on adapter-tagged amplicon 338. Adapters 334 and 336 can hybridize with primers 340 and 342. One or more primers 340 and 342 can be PCR amplification primers. One or more primers 340 and 342 can be sequencing primers. One or more adapters 334 and 336 can be used to further amplify adapter-tagged amplicon 338. One or more adapters 334 and 336 can be used to sequence adapter-tagged amplicon 338. Primer 342 can include a plate index 344, so that the amplicon generated using the same set of barcodes or random barcodes 310 can be sequenced in one sequencing reaction using next generation sequencing (NGS).

[0193] Barcoding at the 5' end of nucleic acid targets

[0194] Disclosed herein are systems, methods, compositions and kits for attaching barcodes (e.g., random barcodes) with molecular labels (or molecular indices) to the 5' end of a nucleic acid target (e.g., a deoxyribonucleic acid molecule, and a ribonucleic acid molecule) to be barcoded or labeled. The 5'-based transcript counting methods disclosed herein can complement or supplement, for example, 3'-based transcript counting methods (e.g., Rhapsody TM Assay (Becton Dickinson, Franklin Lakes, NJ), Chromium TM Single Cell 3' Solution (10X Genetics, San Francisco, CA). Barcoded nucleic acid targets can be used for sequence identification, transcript counting, alternative splicing analysis, mutation screening, and / or full-length sequencing in a high-throughput manner. Transcript counting for the 5' end (5' relative to the target nucleic acid target being labeled) can reveal alternative splicing isomers and variants (including but not limited to splicing variants, single nucleotide polymorphisms (SNPs), insertions, deletions, substitutions) at or near the 5' end of the nucleic acid molecule. In some embodiments, the method can involve intramolecular hybridization.

[0195] Figure 4A-4B A schematic diagram of a non-limiting exemplary method 400 for gene-specifically labeling a nucleic acid target at the 5' end is shown. A barcode 420 (e.g., a random barcode) having a target binding region (e.g., a poly(dT) tail 422) can be bound to a polyadenylated RNA transcript 424 or other nucleic acid target via a poly(dA) tail 426 for labeling or barcoding (e.g., unique labeling). The barcode 420 can include a molecular marker (ML) 428 and a sample marker (SL) 430 for respectively labeling the transcript 424 and tracking the sample source of the RNA transcript 424, as well as one or more additional sequences (e.g., a consensus sequence, such as an adapter sequence 432) flanking the molecular marker 428 / sample marker 430 region of each barcode 420 for subsequent reactions. The sequence library of molecular markers in the barcode of each sample can be large enough for random labeling of RNA transcripts.

[0196] After cDNA synthesis at box 402 to produce a barcoded cDNA molecule 434 comprising an RNA transcript 424 (or a portion thereof), a gene-specific method can be used to perform 5' molecular barcoding. After gene-specific amplification at box 404 (which can be optional), terminal transferase and deoxyadenosine triphosphate (dATP) can be added at box 406 to promote 3' poly (dA) tailing, thereby producing an amplicon 436 with a poly (A) tail 438. A short denaturation step at box 408 allows separation of the forward strand 436m and reverse strand 436c of the amplicon 436 (e.g., a barcoded cDNA molecule with a poly (dA) tail). At box 410, the reverse strand 436c of the amplicon 436 can hybridize intramolecularly through the poly (dA) tail 438 at its 3' end and the poly (dT) region 422 end of the strand to form a hairpin or stem loop 440. Then at block 412, a polymerase (e.g., Klenow fragment) can be used to extend from the poly (dA) tail 438 to replicate the barcode to form an extended barcoded reverse strand 442. Gene-specific amplification at block 414 can then be performed (e.g., optionally) to amplify the gene of interest to produce an amplicon 444 with a barcode at the 5' end (relative to the RNA transcript 424) for sequencing at block 416. In some embodiments, method 400 includes one or both of gene-specific amplification of barcoded cDNA molecules 434 at block 404 and gene-specific amplification of extended barcoded reverse strand 442 at block 414.

[0197] Figure 5A-Figure 5B A schematic diagram of a non-limiting exemplary method 500 for labeling a nucleic acid target on the 5' end for whole transcriptome analysis is shown. A barcode 420 (e.g., a random barcode) having a target binding region (e.g., a poly(dT) tail 422) can be bound to a polyadenylated RNA transcript 424 or other nucleic acid target via a poly(dA) tail 426 for labeling or barcoding (e.g., unique labeling). For example, a barcode 420 having a target binding region can be bound to a nucleic acid target for labeling or barcoding. The barcode 420 can include a molecular marker (ML) 428 and a sample marker (SL) 430. Molecular markers 428 and sample markers 430 can be used to label transcripts 424 or nucleic acid targets (e.g., antibody oligonucleotides, whether associated with or dissociated from the antibody) and track the sample source of transcripts 424, respectively, along with one or more additional sequences (e.g., consensus sequences, such as adapter sequences 432) that flank the molecular marker 428 / sample marker 430 region of each barcode 420 for subsequent reactions. The sequence library of molecular markers 428 in the barcode of each sample can be large enough to stochastically label RNA transcripts 424 or nucleic acid targets.

[0198] After cDNA is synthesized at box 402 to produce barcoded cDNA molecules 434, the 3' end of the barcoded cDNA molecules 434 (equivalent to the 5' end of the labeled RNA transcript) can be A-tailed at box 406 using terminal transferase to produce cDNA molecules 436c each having a 3' poly (dA) tail 438. Intramolecular hybridization of the cDNA molecule 436c having a 3' poly(dA) tail 438 can be initiated (e.g., by heating and cooling cycles, or by dilution of the barcoded cDNA molecule 436c having a poly(dA) tail 438) such that the new 3' poly(dA) tail 438 anneals with the poly(dT) tail of the same labeled cDNA molecule (although it is contemplated that for target binding region sequences other than poly(dA), the corresponding complement of the relevant target binding sequence can anneal to the target binding region) 422 to produce a barcoded cDNA molecule hairpin or stem-loop structure 440 at block 410. At block 412, a polymerase (e.g., Klenow enzyme) and dNTPs can be added to promote 3' extension beyond the new 3' poly(dA) tail 438, thereby replicating the barcode (e.g., molecular tag 428, which is located at the 5' end of the labeled cDNA molecule with stem-loop 440). Whole transcriptome amplification (WTA) can be performed at box 414 using a mirrored adapter 432, 432rc or a primer containing a sequence (or subsequence) of the adapter 432, 432rc. Methods such as tagging or random priming can be used at box 418 to generate smaller amplicon 444 fragments with sequencing adapters (e.g., P5 446 and P7 448 sequences) for sequencing (e.g., using an Illumina (San Diego, California, USA) sequencer). In some embodiments, sequencing adapters for other sequencing methods or sequencers (e.g., sequencers from Pacific Biosciences of California, Inc. (Menlo Park, California, USA) or Oxford Nanopore Technologies Limited (Oxford, UK)) can be directly connected to generate amplicons for sequencing.

[0199] Disclosed herein are methods for determining the number of nucleic acid targets in a sample. In some embodiments, the method includes: contacting a copy of a nucleic acid target 424 in the sample with a plurality of oligonucleotide barcodes 420, wherein each of the plurality of oligonucleotide barcodes 420 comprises a molecular marker sequence 428 and a target binding region (e.g., a poly (dT) sequence 422) capable of hybridizing with the nucleic acid target 424, and wherein at least 10 of the plurality of oligonucleotide barcodes 420 comprise different molecular marker sequences 428; at block 402, extending the nucleic acid target 424 hybridized with the oligonucleotide barcode 420; 4 to produce a plurality of nucleic acid molecules 434, each nucleic acid molecule 434 comprising a sequence 450c complementary to at least a portion of nucleic acid target 424; at block 404, amplifying the plurality of barcoded nucleic acid molecules 434 to produce a plurality of amplified barcoded nucleic acid molecules 436; at block 406, attaching an oligonucleotide comprising a complement 438 of target binding region 422 to the plurality of amplified barcoded nucleic acid molecules 436 to produce a plurality of barcoded nucleic acid molecules 436c, each barcoded nucleic acid molecule 436c The barcoded nucleic acid molecule 436c comprises a target binding region 422 and a complement 438 of the target binding region; at block 410, the target binding region 422 and the complement 438 of the target binding region 422 within each of the plurality of barcoded nucleic acid molecules 436c are hybridized to form a stem-loop 440; at block 412, the 3' ends of the plurality of barcoded nucleic acid molecules each having the stem-loop 440 are extended to extend the stem-loop 440 to generate a plurality of extended barcoded nucleic acid molecules 442, each of which has a plurality of barcoded nucleic acid molecules 443. The barcoded nucleic acid molecule 442 comprises a molecular tag 428 and a complement 428rc of the molecular tag; at box 414, a plurality of extended barcoded nucleic acid molecules 442 are amplified to produce a plurality of singly labeled nucleic acid molecules 444c, each singly labeled nucleic acid molecule 444c comprising a complement 428rc of the molecular tag; and based on the number of complementary sequences 428rc of the molecular tags having different sequences associated with the plurality of singly labeled nucleic acid molecules, the number of nucleic acid targets in the sample is determined.

[0200] In some embodiments, after extending the 3' ends of the plurality of barcoded nucleic acid molecules having stem-loops 440, the molecular tag 428 is hybridized to the complement 428rc of the molecular tag. The method may include denaturing the plurality of extended barcoded nucleic acid molecules 442 before amplifying the plurality of extended barcoded nucleic acid molecules 442 to produce a plurality of single labeled nucleic acid molecules 444c (which may be part of the amplicons 444c). Contacting the copies of the nucleic acid targets 424 in the sample may include contacting the copies of the plurality of nucleic acid targets 424 with the plurality of oligonucleotide barcodes 420. Extending the copies of the nucleic acid targets 424 may include extending the copies of the plurality of nucleic acid targets 424 hybridized with the oligonucleotide barcodes 420 to produce a plurality of barcoded nucleic acid molecules 436c, each barcoded nucleic acid molecule 436c comprising a sequence 450c complementary to at least a portion of one of the plurality of nucleic acid targets 424. Determining the number of nucleic acid targets 424 may include determining the number of each of the plurality of nucleic acid targets 424 in the sample based on the number of complementary sequences 428rc of molecular tags having different sequences associated with the single-labeled nucleic acid molecules of the plurality of single-labeled nucleic acid molecules 444c that include the sequence 452c of each of the plurality of nucleic acid targets 424. The sequence 452c of each of the plurality of nucleic acid targets may include a subsequence (including a complement or a reverse complement) of each of the plurality of nucleic acid targets 424.

[0201] Disclosed herein are methods for determining the number of targets in a sample. In some embodiments, the method includes: barcoding copies of a nucleic acid target 424 in a sample using a plurality of oligonucleotide barcodes 420 to generate a plurality of barcoded nucleic acid molecules 434, each barcoded nucleic acid molecule 434 comprising a sequence 450c of the nucleic acid target 424 (e.g., a complementary sequence, a reverse complementary sequence, or a combination thereof), a molecular marker 428, and a target binding region (e.g., a poly (dT) region 422), and wherein at least 10 of the plurality of oligonucleotide barcodes 420 comprise a different molecular marker sequence 428; attaching 406 an oligonucleotide comprising a complement 438 of the target binding region 422 to the plurality of barcoded nucleic acid molecules 434 to generate a plurality of barcoded nucleic acid molecules 436, each barcoded nucleic acid molecule 434 comprising a sequence 450c of the nucleic acid target 424 (e.g., a complementary sequence, a reverse complementary sequence, or a combination thereof), a molecular marker 428, and a target binding region (e.g., a poly (dT) region 422); The nucleic acid molecule 436 comprises a target binding region 422 and a complement 438 of the target binding region 422; hybridizing 410 the target binding region 422 and the complement 438 of the target binding region within each of a plurality of barcoded nucleic acid molecules 436c to form a stem-loop 440; extending 412 the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem-loop 440 to produce a plurality of extended barcoded nucleic acid molecules 442, each extended barcoded nucleic acid molecule 442 comprising a molecular marker 428 and a complement 428rc of the molecular marker; and determining the number of nucleic acid targets 424 in the sample based on the number of complementary sequences 428rc of the molecular markers having different sequences associated with the plurality of extended barcoded nucleic acid molecules 442.

[0202] Disclosed herein are methods for attaching oligonucleotide barcodes to targets in a sample. In some embodiments, the method includes: barcoding copies of a nucleic acid target 424 in a sample using a plurality of oligonucleotide barcodes 420 to produce a plurality of barcoded nucleic acid molecules 434, each barcoded nucleic acid molecule 434 comprising a sequence 450c of a nucleic acid target 424, a molecular marker 428, and a target binding region 422, and wherein at least 10 of the plurality of oligonucleotide barcodes 420 comprise different molecular marker sequences 428; attaching an oligonucleotide comprising a complement 438 of the target binding region 422 to the plurality of barcoded nucleic acid molecules 434 to produce a plurality of barcoded nucleic acid molecules; The method comprises: hybridizing 410 the target binding region 422 and the complement 438 of the target binding region 422 within each of the plurality of barcoded nucleic acid molecules 436c to form a stem-loop 440; and extending 412 the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem-loop 440 to produce a plurality of extended barcoded nucleic acid molecules 442, each of the extended barcoded nucleic acid molecules 442 comprising a molecular tag 428 and a complement 428rc of the molecular tag 428. In some embodiments, the method comprises: determining the number of nucleic acid targets 424 in the sample based on the number of molecular tags 428 with different sequences, their complements 428rc, or a combination thereof associated with the plurality of extended barcoded nucleic acid molecules 442. For example, the amount of nucleic acid target 424 can be determined based on molecular markers 428 having different sequences, one of their complementary sequences 428rc, or both.

[0203] In some embodiments, the method includes: barcoding 402 copies of multiple targets 424, including: contacting the copies of the nucleic acid target 424 with multiple oligonucleotide barcodes 420, wherein each of the multiple oligonucleotide barcodes 420 comprises a target binding region 422 capable of hybridizing with the nucleic acid target 424; and then extending 402 the copies of the nucleic acid target 424 hybridized with the oligonucleotide barcodes 420 to produce multiple barcoded nucleic acid molecules 434.

[0204] In some embodiments, the method includes: amplifying 404 multiple barcoded nucleic acid molecules 434 to produce multiple amplified barcoded nucleic acid molecules 436c, wherein attaching an oligonucleotide comprising a complement 438 of the target binding region 422 includes: attaching an oligonucleotide comprising a complement 438 of the target binding region to multiple amplified barcoded nucleic acid molecules to produce multiple barcoded nucleic acid molecules 436r, each barcoded nucleic acid molecule 436r comprising a target binding region 422 and a complement 438 of the target binding region.

[0205] Gene-specific analysis In some embodiments, the method (e.g., method 400) includes amplifying 414 a plurality of extended barcoded nucleic acid molecules 442 to produce a plurality of singly labeled nucleic acid molecules 444c, each singly labeled nucleic acid molecule 444c comprising a complement 428rc of a molecular marker 428. When the amplicon 444 comprising the singly labeled nucleic acid molecule 444c is denatured, the singly labeled nucleic acid molecule 444c may be produced. Determining the number of nucleic acid targets 424 in the sample may include determining the number of nucleic acid targets 424 in the sample based on the number of complementary sequences 428rc of the molecular marker 428 having different sequences associated with the plurality of singly labeled nucleic acid molecules 444c.

[0206] Whole transcriptome analysis In some embodiments, the method (e.g., method 500) includes amplifying 414 a plurality of extended barcoded nucleic acid molecules 442 to produce a plurality of extended barcoded nucleic acid molecule copies 444c. Determining the number of nucleic acid targets 424 in the sample includes determining the number of nucleic acid targets 424 in the sample based on the number of complementary sequences 428rc of molecular markers 428 having different sequences associated with the plurality of extended barcoded nucleic acid molecule copies 444c. When the amplicon 444 comprising the plurality of extended barcoded nucleic acid molecule copies 444c is denatured, the plurality of extended barcoded nucleic acid molecule copies 444c may be formed.

[0207] In some embodiments, the sequence of the nucleic acid target in the plurality of barcoded nucleic acid molecules comprises a subsequence 452c of the nucleic acid target. The target binding region may comprise a gene-specific sequence. Attaching 406 an oligonucleotide comprising a complement 438 of the target binding region 422 may comprise connecting the oligonucleotide comprising a complement 438 of the target binding region 422 to the plurality of barcoded nucleic acid molecules 434.

[0208] In some embodiments, the target binding region may comprise a poly(dT) sequence 422 (which may also be referred to herein as an oligo(dT) sequence). Attaching an oligonucleotide comprising a complement 438 of the target binding region 422 comprises using a terminal deoxynucleotidyl transferase to add a plurality of adenosine monophosphates to the plurality of barcoded nucleic acid molecules 434. In some embodiments, the target binding region does not comprise a poly(dT) sequence.

[0209] In some embodiments, extending the copies of the nucleic acid target 424 hybridized to the oligonucleotide barcode 420 may include reverse transcribing the copies of the nucleic acid target 424 hybridized to the oligonucleotide barcode 420 to generate a plurality of barcoded complementary deoxyribonucleic acid (cDNA) molecules 434. Extending the copies of the nucleic acid target 424 hybridized to the oligonucleotide barcode 420 may include extending 402 the copies of the nucleic acid target 424 hybridized to the oligonucleotide barcode 420 using a DNA polymerase lacking at least one of a 5' to 3' exonuclease activity and a 3' to 5' exonuclease activity. The DNA polymerase may comprise a Klenow fragment.

[0210] In some embodiments, the method includes obtaining sequence information of the plurality of extended barcoded nucleic acid molecules 442. Obtaining the sequence information may include attaching sequencing adapters (eg, P5 446 and P7 448 adapters) to the plurality of extended barcoded nucleic acid molecules 442.

[0211] In some embodiments, the complement 438 of the target binding region may include the reverse complement sequence of the target binding region. The complement 438 of the target binding region may include the complementary sequence of the target binding region. The complement 428rc of the molecular marker may include the reverse complement sequence of the molecular marker. The complement of the molecular marker may include the complementary sequence of the molecular marker.

[0212] In some embodiments, the plurality of barcoded nucleic acid molecules 434 may include barcoded deoxyribonucleic acid (DNA) molecules. The barcoded nucleic acid molecules 434 may include barcoded ribonucleic acid (RNA) molecules. The nucleic acid target 424 may include nucleic acid molecules. The nucleic acid molecules may include ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA containing a poly (A) tail, or any combination thereof.

[0213] Antibody Oligonucleotides . In some embodiments, the nucleic acid target may include a cellular component binding reagent. Cell binding reagents associated with nucleic acid targets (e.g., antibody oligonucleotides, such as sample indexing oligonucleotides) have been described in US2018 / 0088112; and U.S. Application No. 15 / 937,713 filed on March 27, 2018; the contents of each of these applications are incorporated herein by reference in their entirety. In some embodiments, the 5' barcoding method disclosed herein can be used to obtain multi-omics information of single cells, such as genomics, chromatin accessibility, methylomes, transcriptomics, and proteomics. Nucleic acid molecules can be associated with cellular component binding reagents. The method may include: dissociating the nucleic acid molecule and the cellular component binding reagent.

[0214] In some embodiments, each molecular label 428 of the plurality of oligonucleotide barcodes 420 comprises at least 6 nucleotides. The oligonucleotide barcodes 420 may comprise the same sample label 430. Each sample label 430 of the plurality of oligonucleotide barcodes 420 may comprise at least 6 nucleotides. The oligonucleotide barcodes 420 may comprise the same cell label. Each cell label of the plurality of oligonucleotide barcodes 420 may comprise at least 6 nucleotides.

[0215] In some embodiments, at least one of the plurality of barcoded nucleic acid molecules 436c is associated with a solid support when the target binding region and the complement of the target binding region within each of the plurality of barcoded nucleic acid molecules are hybridized 410 to form a stem-loop. At least one of the plurality of barcoded nucleic acid molecules 436c can be dissociated from the solid support when the target binding region 422 and the complement 438 of the target binding region 422 within each of the plurality of barcoded nucleic acid molecules 436c are hybridized 410 to form a stem-loop 440. At least one of the plurality of barcoded nucleic acid molecules 436c can be associated with a solid support when the target binding region 422 and the complement 438 of the target binding region within each of the plurality of barcoded nucleic acid molecules 436c are hybridized 410 to form a stem-loop 440.

[0216] In some embodiments, when the 3' ends of the plurality of barcoded nucleic acid molecules are extended 412 to extend the stem-loop 440 to generate a plurality of extended barcoded nucleic acid molecules 442 (each extended barcoded nucleic acid molecule 442 includes a molecular tag 428 and a complement of the molecular tag 428rc), at least one of the plurality of barcoded nucleic acid molecules is associated with a solid support. When the 3' ends of the plurality of barcoded nucleic acid molecules are extended 412 to extend the stem-loop 440 to generate a plurality of extended barcoded nucleic acid molecules 442 (each extended barcoded nucleic acid molecule 442 includes a molecular tag 428 and a complement of the molecular tag 428rc), at least one of the plurality of barcoded nucleic acid molecules may be dissociated from the solid support. When the 3' ends of the plurality of barcoded nucleic acid molecules are extended 412 to extend the stem loop 440 to generate a plurality of extended barcoded nucleic acid molecules 442 (each extended barcoded nucleic acid molecule 442 comprising a molecular tag 428 and a complement 428rc of the molecular tag), at least one of the plurality of barcoded nucleic acid molecules 436c can be associated with a solid support. The solid support can comprise a synthetic particle 454. The solid support can comprise a flat surface or a substantially flat surface (e.g., a slide, such as a microscope slide or a cover slip).

[0217] In some embodiments, at least one of the plurality of barcoded nucleic acid molecules 436c is in solution when hybridizing 410 the target binding region 422 and the complement 438 of the target binding region 422 within each of the plurality of barcoded nucleic acid molecules 436c to form a stem-loop 440. For example, such intramolecular hybridization may occur when the concentration of the plurality of barcoded nucleic acid molecules 436c in the solution is sufficiently low. At least one of the plurality of barcoded nucleic acid molecules may be in solution when the 3' ends of the plurality of barcoded nucleic acid molecules are extended 412 to extend the stem-loop 440 to produce a plurality of extended barcoded nucleic acid molecules 442, each of which comprises a molecular tag 428 and a complement 428rc of the molecular tag.

[0218] In some embodiments, the sample includes a single cell and the method includes associating a synthetic particle 454 comprising a plurality of oligonucleotide barcodes 420 with a single cell in the sample. The method may include, after associating the synthetic particle 454 with the single cell, lysing the single cell. Lysing the single cell may include heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof. The synthetic particle and the single cell may be in the same well. The synthetic particle and the single cell may be in the same drop.

[0219] In some embodiments, at least one of the plurality of oligonucleotide barcodes 420 may be immobilized on a synthetic particle 454. At least one of the plurality of oligonucleotide barcodes 420 may be partially immobilized on a synthetic particle 454. At least one of the plurality of oligonucleotide barcodes 420 may be enclosed in a synthetic particle 454. At least one of the plurality of oligonucleotide barcodes 420 may be partially enclosed in a synthetic particle 454. The synthetic particle 454 may be destructible. The synthetic particle 454 may comprise a bead. The bead may comprise a cross-linked agarose (Sepharose) bead, a streptavidin bead, an agarose bead, a magnetic bead, a conjugated bead, a protein A conjugated bead, a protein G conjugated bead, a protein A / G conjugated bead, a protein L conjugated bead, an oligo(dT) conjugated bead, a silica bead, a silica-like bead, an anti-biotin microbead, an anti-fluorescent dye microbead, or any combination thereof. The synthetic particles 454 may comprise a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof. The synthetic particles 454 may comprise destructible hydrogel particles. Each of the plurality of oligonucleotide barcodes 420 may comprise a linker functional group. The synthetic particles 454 may comprise a solid support functional group. The support functional group and the linker functional group may be associated with each other. The linker functional group and the support functional group may be individually selected from the group consisting of C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof.

[0220] Kit for barcoding at the 5' end of nucleic acid targets

[0221] Disclosed herein is a kit for attaching an oligonucleotide barcode 420 to a target 424 in a sample, determining the number of targets 424 in a sample, and / or determining the number of nucleic acid targets 424 in a sample. In some embodiments, the kit includes: a plurality of oligonucleotide barcodes 420, wherein each of the plurality of oligonucleotide barcodes 420 comprises a molecular marker 428 and a target binding region (e.g., a poly (dT) sequence 422), and wherein at least 10 of the plurality of oligonucleotide barcodes 420 comprise different molecular marker sequences 428; a terminal deoxynucleotidyl transferase or a ligase; and a DNA polymerase lacking at least one of a 5' to 3' exonuclease activity and a 3' to 5' exonuclease activity. The kit may include a plurality of oligonucleotides comprising complements of the target binding region. A plurality of oligonucleotides comprising complements of the target binding region may be separated from a plurality of oligonucleotide barcodes. In some embodiments, a plurality of oligonucleotides comprising complements of the target binding region are configured to be attached to the 3' end of a DNA molecule, such as a cDNA molecule. A plurality of oligonucleotides comprising a complement of the target binding region can be used to hybridize with the target binding region, so that the DNA molecule forms a hairpin as described herein. The DNA polymerase can comprise a Klenow fragment. The kit can comprise a buffer. The kit can comprise a column. The kit can comprise one or more reagents for a reverse transcription reaction. The kit can comprise one or more reagents for an amplification reaction.

[0222] In some embodiments, the target binding region comprises a gene-specific sequence, an oligo (dT) sequence, a random polymer, or any combination thereof. The oligonucleotide barcode may comprise the same sample marker and / or the same cell marker. Each sample marker and / or cell marker of a plurality of oligonucleotide barcodes may comprise at least 6 nucleotides. Each molecular marker of a plurality of oligonucleotide barcodes may comprise at least 6 nucleotides.

[0223] In some embodiments, at least one of the plurality of oligonucleotide barcodes 420 is immobilized on a synthetic particle 454. At least one of the plurality of oligonucleotide barcodes 420 may be partially immobilized on a synthetic particle 454. At least one of the plurality of oligonucleotide barcodes 420 may be enclosed in a synthetic particle 454. At least one of the plurality of oligonucleotide barcodes 420 may be partially enclosed in a synthetic particle 454. The synthetic particle 454 may be destructible. The synthetic particle 454 may comprise a bead. The bead may comprise a cross-linked agarose (Sepharose) bead, a streptavidin bead, an agarose bead, a magnetic bead, a conjugated bead, a protein A conjugated bead, a protein G conjugated bead, a protein A / G conjugated bead, a protein L conjugated bead, an oligo(dT) conjugated bead, a silica bead, a silica-like bead, an anti-biotin microbead, an anti-fluorescent dye microbead, or any combination thereof. The synthetic particles can include materials selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof. The synthetic particles 454 can include destructible hydrogel particles. Each of the multiple oligonucleotide barcodes can include a linker functional group. The synthetic particles 454 can include a solid support functional group. The support functional group and the linker functional group can be associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof.

[0224] Although various aspects and embodiments have been disclosed herein, other methods and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

[0225] Those skilled in the art will appreciate that for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in different orders. In addition, the steps and operations outlined are provided only as examples, and certain steps and operations may be optional, may be combined into fewer steps and operations, or may be expanded into additional steps and operations without departing from the essence of the disclosed embodiments.

[0226] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art may translate the plural into the singular and / or the singular into the plural as the context and / or application requires. For the sake of clarity, various singular / plural conversions may be explicitly listed herein.

[0227] Those skilled in the art will understand that, in general, the terms used herein, especially in the appended claims (e.g., the bodies of the appended claims), are generally intended to be "open" terms (e.g., the term "including" should be interpreted as "including but not limited to", the term "having" should be interpreted as "having at least", the term "includes" should be interpreted as "including but not limited to", etc.). Those of ordinary skill in the art will further recognize that if a specific number of an introduced claim statement is intended, such intent will be explicitly stated in the claim, and in the absence of such a statement, such intent is not presented. For example, to aid understanding, the following appended claims may include the use of the introductory phrases "at least one" and "one or more" to introduce claim statements. However, the use of such phrases should not be construed as meaning that introducing a claim recitation via the indefinite article "a" or "an" limits any particular claim containing such an introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should also be construed to mean "at least one" or "one or more"); the same applies to the use of definite articles to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly stated, one skilled in the art will recognize that this recitation should also be construed to mean at least that number of recitations (e.g., merely stating "two recitations" without other modifiers means at least two recitations, or two or more recitations). Furthermore, where a convention similar to “at least one of A, B, and C, etc.” is used, generally such syntactic construction is intended to mean that a person skilled in the art will understand the convention in a sense (e.g., “a system having at least one of A, B, and C” will include, but is not limited to, systems having only A, only B, only C, both A and B, both A and C, both B and C, and / or both A, B, and C, etc.). Where a convention similar to “at least one of A, B, and C, etc.” is used, generally such syntactic construction is intended to mean that a person skilled in the art will understand the convention in a sense (e.g., “a system having at least one of A, B, or C” will include, but is not limited to, systems having only A, only B, only C, both A and B, both A and C, both B and C, and / or both A, B, and C, etc.). A person of ordinary skill in the art will further understand that almost any disjunctive word and / or phrase presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one, either, or both of these terms.For example, the phrase "A or B" should be understood to include the possibilities of "A" or "B" or "A and B."

[0228] In addition, where various features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also described in terms of any individual member or subgroup of multiple members of the Markush group.

[0229] As will be understood by those skilled in the art, for any and all purposes such as in terms of providing a written description, all ranges disclosed herein also include any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily considered to have been fully described and to divide the same range into at least equal halves, trisections, quarters, quintiles, deciles, etc. As a non-limiting example, each range discussed herein can be easily divided into the lower third, middle third, and upper third, etc. As will be understood by those skilled in the art, all such as "up to", "at least" and other languages ​​include the mentioned numerical values, and refer to the ranges that can then be divided into the sub-ranges discussed above. Finally, as will be understood by those skilled in the art, a range includes each independent member. Therefore, for example, a group with 1-3 cells refers to a group with 1, 2 or 3 cells. Similarly, a group with 1-5 cells refers to a group with 1, 2, 3, 4 or 5 cells, etc.

[0230] From the foregoing, it will be understood that various embodiments of the present disclosure have been described herein for illustrative purposes, and that various modifications may be made without departing from the scope and spirit of the present disclosure. Therefore, the various embodiments disclosed herein are not intended to be limiting, with the true scope and spirit being indicated by the appended claims.

[0231] This application also provides the following items:

[0232] 1. A method for attaching an oligonucleotide barcode to a nucleic acid target in a sample, the method comprising:

[0233] barcoding copies of the nucleic acid target in the sample using a plurality of oligonucleotide barcodes to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences;

[0234] attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to generate a plurality of elongated barcoded nucleic acid molecules, each elongated barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region;

[0235] hybridizing the target binding region and a complement of the target binding region within each of the plurality of elongated barcoded nucleic acid molecules to form a stem-loop; and

[0236] The 3' ends of the plurality of extended barcoded nucleic acid molecules are extended to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each of which comprises the molecular tag and a complement of the molecular tag.

[0237] 2. The method described in item 1 further comprises: determining the quantity of the nucleic acid target in the sample based on the quantity of molecular markers with different sequences, their complementary sequences or a combination thereof associated with the multiple extended barcoded nucleic acid molecules.

[0238] 3. A method for determining the amount of a target in a sample, the method comprising:

[0239] barcoding copies of a nucleic acid target in a sample using a plurality of oligonucleotide barcodes to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences;

[0240] attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to generate a plurality of elongated barcoded nucleic acid molecules, each elongated barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region;

[0241] hybridizing the target binding region and a complement of the target binding region within each of the plurality of elongated barcoded nucleic acid molecules to form a stem-loop;

[0242] extending the 3' ends of the plurality of extended barcoded nucleic acid molecules to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the molecular tag and a complement of the molecular tag; and

[0243] The quantity of the nucleic acid target in the sample is determined based on the quantity of complementary sequences of the molecular tags having different sequences associated with the plurality of extended barcoded nucleic acid molecules.

[0244] 4. The method of any one of items 1-3, wherein barcoding the copies of the plurality of targets comprises:

[0245] contacting a copy of the nucleic acid target with the plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a target binding region capable of hybridizing to the nucleic acid target; and

[0246] Copies of the nucleic acid target hybridized to the oligonucleotide barcode are extended to generate a plurality of barcoded nucleic acid molecules.

[0247] 5. The method of any one of items 1-3, wherein barcoding the copies of the plurality of targets comprises:

[0248] contacting a copy of the nucleic acid target with the plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises the target binding region, wherein the target binding region hybridizes to the nucleic acid target; and

[0249] Copies of the nucleic acid target hybridized to the oligonucleotide barcode are extended to generate a plurality of barcoded nucleic acid molecules.

[0250] 6. The method according to any one of items 1 to 5,

[0251] The method comprises amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules,

[0252] Wherein attaching the oligonucleotide comprising the complement of the target binding region comprises: attaching the oligonucleotide comprising the complement of the target binding region to the plurality of amplified barcoded nucleic acid molecules to generate a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the target binding region and the complement of the target binding region.

[0253] 7. The method according to any one of items 2 to 6,

[0254] The method includes amplifying the plurality of extended barcoded nucleic acid molecules to produce a plurality of singly labeled nucleic acid molecules, each singly labeled nucleic acid molecule comprising the complement of the molecular tag;

[0255] Wherein determining the quantity of the nucleic acid target in the sample comprises: determining the quantity of the nucleic acid target in the sample based on the quantity of complementary sequences of the molecular labels with different sequences associated with the plurality of singly labeled nucleic acid molecules.

[0256] 8. The method according to any one of items 2 to 6,

[0257] The method comprises amplifying the plurality of extended barcoded nucleic acid molecules to generate copies of the plurality of extended barcoded nucleic acid molecules,

[0258] Wherein determining the quantity of the nucleic acid target in the sample comprises determining the quantity of the nucleic acid target in the sample based on the quantity of complementary sequences of molecular markers having different sequences associated with the copies of the plurality of extended barcoded nucleic acid molecules.

[0259] 9. A method for determining the amount of a nucleic acid target in a sample, the method comprising:

[0260] contacting a copy of a nucleic acid target in a sample with a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region capable of hybridizing to the nucleic acid target, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences;

[0261] extending copies of the nucleic acid target hybridized to the oligonucleotide barcode to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target;

[0262] amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules;

[0263] attaching an oligonucleotide comprising a complement of the target binding region to the plurality of amplified barcoded nucleic acid molecules to generate a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region;

[0264] hybridizing the target binding region and a complement of the target binding region within each of the plurality of elongated barcoded nucleic acid molecules to form a stem-loop;

[0265] extending the 3' ends of the plurality of extended barcoded nucleic acid molecules to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the molecular tag and a complement of the molecular tag;

[0266] amplifying the plurality of extended barcoded nucleic acid molecules to produce a plurality of singly labeled nucleic acid molecules, each singly labeled nucleic acid molecule comprising the complement of the molecular tag; and

[0267] The quantity of the nucleic acid target in the sample is determined based on the quantity of complementary sequences of the molecular labels having different sequences associated with the plurality of singly labeled nucleic acid molecules.

[0268] 10. A method as described in any of items 7-9, wherein after extending the 3' ends of the multiple extended barcoded nucleic acid molecules, the molecular tag is hybridized with the complement of the molecular tag, and the method includes denaturing the multiple extended barcoded nucleic acid molecules and then amplifying the multiple extended barcoded nucleic acid molecules to produce the multiple single-labeled nucleic acid molecules.

[0269] 11. The method according to any one of items 9 to 10,

[0270] wherein contacting the copies of the nucleic acid target in the sample comprises contacting a plurality of copies of the nucleic acid target with a plurality of oligonucleotide barcodes,

[0271] wherein extending the copies of the nucleic acid target comprises extending the copies of the plurality of nucleic acid targets hybridized to the oligonucleotide barcode to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence complementary to at least a portion of one of the plurality of nucleic acid targets, and

[0272] Wherein determining the quantity of the nucleic acid targets comprises determining the quantity of each of the plurality of nucleic acid targets in the sample based on the quantity of complementary sequences of molecular labels having different sequences associated with single-labeled nucleic acid molecules among a plurality of single-labeled nucleic acid molecules comprising the sequence of each of the plurality of nucleic acid targets.

[0273] 12. The method of claim 11, wherein the sequence of each of the plurality of nucleic acid targets comprises a subsequence of each of the plurality of nucleic acid targets.

[0274] 13. The method of any one of items 1-12, wherein the sequence of the nucleic acid target in the plurality of barcoded nucleic acid molecules comprises a subsequence of the nucleic acid target.

[0275] 14. A method as described in any of items 1-13, wherein the target binding region comprises a gene-specific sequence.

[0276] 15. The method of any one of items 1-14, wherein attaching the oligonucleotide comprising the complement of the target binding region comprises: connecting the oligonucleotide comprising the complement of the target binding region to the plurality of barcoded nucleic acid molecules.

[0277] 16. The method according to any one of items 1 to 12,

[0278] wherein the target binding region comprises a poly(dT) sequence, and

[0279] Wherein attaching the oligonucleotide comprising the complement of the target binding region comprises adding a plurality of adenosine monophosphates to the plurality of barcoded nucleic acid molecules using terminal deoxynucleotidyl transferase.

[0280] 17. A method as described in any of items 4-16, wherein extending the copy of the nucleic acid target hybridized to the oligonucleotide barcode includes reverse transcribing the copy of the nucleic acid target hybridized to the oligonucleotide barcode to produce a plurality of barcoded complementary deoxyribonucleic acid (cDNA) molecules.

[0281] 18. A method as described in any of items 4-16, wherein extending the copy of the nucleic acid target hybridized to the oligonucleotide barcode comprises extending the copy of the nucleic acid target hybridized to the oligonucleotide barcode using a DNA polymerase lacking at least one of 5' to 3' exonuclease activity and 3' to 5' exonuclease activity.

[0282] 19. A method as described in item 18, wherein the DNA polymerase comprises a Klenow fragment.

[0283] 20. The method of any one of items 1-19, comprising obtaining sequence information of the plurality of extended barcoded nucleic acid molecules.

[0284] 21. A method as described in item 20, wherein obtaining the sequence information includes attaching sequencing adapters to the plurality of extended barcoded nucleic acid molecules.

[0285] 22. The method of any one of items 1-21, wherein the complement of the target binding region comprises the reverse complement sequence of the target binding region.

[0286] 23. A method as described in any of items 1-21, wherein the complement of the target binding region comprises a complementary sequence of the target binding region.

[0287] 24. A method as described in any one of items 1-23, wherein the complement of the molecular marker comprises the reverse complementary sequence of the molecular marker.

[0288] 25. The method of any one of items 1-23, wherein the complement of the molecular marker comprises a complementary sequence of the molecular marker.

[0289] 26. The method of any one of items 1-25, wherein the plurality of barcoded nucleic acid molecules comprises barcoded deoxyribonucleic acid (DNA) molecules.

[0290] 27. The method of any one of items 1-25, wherein the barcoded nucleic acid molecules comprise barcoded ribonucleic acid (RNA) molecules.

[0291] 28. The method of any one of items 1-27, wherein the nucleic acid target comprises, consists essentially of, or consists of a nucleic acid molecule.

[0292] 29. A method as described in item 28, wherein the nucleic acid molecule comprises ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA containing a poly (A) tail, or any combination thereof.

[0293] 30. A method as described in any of items 28-29, wherein the nucleic acid target comprises a cellular component binding agent.

[0294] 31. A method as described in item 30, wherein the nucleic acid molecule is associated with the cellular component binding reagent.

[0295] 32. A method as described in item 31, which includes dissociating the nucleic acid molecule and the cellular component binding agent.

[0296] 33. A method as described in any of items 1-32, wherein each molecular tag of the plurality of oligonucleotide barcodes comprises at least 6 nucleotides.

[0297] 34. A method as described in any of items 1-33, wherein the oligonucleotide barcodes contain the same sample label.

[0298] 35. A method as described in item 34, wherein each sample label of the multiple oligonucleotide barcodes contains at least 6 nucleotides.

[0299] 36. A method as described in any of items 1-35, wherein the oligonucleotide barcodes contain the same cellular marker.

[0300] 37. A method as described in item 36, wherein each cell marker of the multiple oligonucleotide barcodes contains at least 6 nucleotides.

[0301] 38. A method as described in any of items 1-37, wherein when the target binding region and the complement of the target binding region within each of the multiple extended barcoded nucleic acid molecules are hybridized to form a stem loop, at least one of the multiple extended barcoded nucleic acid molecules is associated with a solid support.

[0302] 39. A method as described in any of items 1-37, wherein when the target binding region and the complement of the target binding region within each of the multiple extended barcoded nucleic acid molecules are hybridized to form a stem loop, at least one of the multiple extended barcoded nucleic acid molecules dissociates from the solid support.

[0303] 40. A method as described in any of items 1-37, wherein when the target binding region and the complement of the target binding region within each of the multiple extended barcoded nucleic acid molecules are hybridized to form a stem loop, at least one of the multiple extended barcoded nucleic acid molecules is associated with a solid support.

[0304] 41. A method as described in any of items 1-37, wherein when the 3' ends of the multiple extended barcoded nucleic acid molecules are extended to extend the stem-loop to produce a plurality of extended barcoded nucleic acid molecules each comprising the molecular marker and the complement of the molecular marker, at least one of the multiple extended barcoded nucleic acid molecules is associated with a solid support.

[0305] 42. A method as described in any of items 1-37, wherein when the target binding region and the complement of the target binding region within each of the multiple extended barcoded nucleic acid molecules are hybridized to form a stem loop, at least one of the multiple extended barcoded nucleic acid molecules dissociates from the solid support.

[0306] 43. A method as described in any of items 1-37, wherein when the 3' ends of the multiple extended barcoded nucleic acid molecules are extended to extend the stem-loop to produce a plurality of extended barcoded nucleic acid molecules each comprising the molecular marker and the complement of the molecular marker, at least one of the multiple extended barcoded nucleic acid molecules is not associated with a solid support.

[0307] 44. A method as described in any of items 38-43, wherein the solid support comprises synthetic particles.

[0308] 45. The method of any one of items 38-43, wherein the solid support comprises a flat surface.

[0309] 46. ​​A method as described in any of items 1-37, wherein at least one of the multiple barcoded nucleic acid molecules is in solution when the target binding region and the complement of the target binding region within each of the multiple extended barcoded nucleic acid molecules are hybridized to form a stem loop.

[0310] 47. A method as described in any of items 1-37, wherein when the 3' ends of the multiple extended barcoded nucleic acid molecules are extended to extend the stem loop to produce a plurality of extended barcoded nucleic acid molecules each comprising the molecular marker and the complement of the molecular marker, at least one of the multiple extended barcoded nucleic acid molecules is in solution.

[0311] 48. A method as described in any of items 46-47, wherein the solution is distributed in a distribution area containing no more than one cell.

[0312] 49. The method of item 48, wherein the dispensing region comprises at least one of a droplet, a microwell, or a chamber of a fluidic device.

[0313] 50. A method as described in any of items 1-49, wherein the sample comprises a single cell, and the method comprises associating a synthetic particle comprising the plurality of oligonucleotide barcodes with the single cell in the sample.

[0314] 51. The method of claim 50, comprising lysing the single cell after associating the synthetic particle with the single cell.

[0315] 52. A method as described in item 51, wherein lysing the single cell includes heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.

[0316] 53. A method as described in any of items 50-52, wherein the synthetic particles and the single cells are in the same well.

[0317] 54. A method as described in any of items 50-53, wherein the synthetic particles and the single cells are in the same droplet.

[0318] 55. A method as described in any of items 50-54, wherein at least one of the multiple oligonucleotide barcodes is immobilized on the synthetic particle.

[0319] 56. A method as described in any of items 50-54, wherein at least one of the multiple oligonucleotide barcodes is partially fixed on the synthetic particle.

[0320] 57. A method as described in any of items 50-54, wherein at least one of the multiple oligonucleotide barcodes is enclosed in the synthetic particle.

[0321] 58. A method as described in any of items 50-54, wherein at least one of the multiple oligonucleotide barcodes is partially enclosed in the synthetic particle.

[0322] 59. A method as described in any of items 50-58, wherein the synthetic particles are destructible.

[0323] 60. A method as described in any of items 50-59, wherein the synthetic particles comprise beads.

[0324] 61. A method as described in item 60, wherein the beads comprise cross-linked agarose beads, streptavidin beads, agarose beads, magnetic beads, conjugated beads, protein A conjugated beads, protein G conjugated beads, protein A / G conjugated beads, protein L conjugated beads, oligo (dT) conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads or any combination thereof.

[0325] 62. A method as described in any of items 60-61, wherein the synthetic particles comprise a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof.

[0326] 63. A method as described in any of items 50-62, wherein the synthetic particles comprise destructible hydrogel particles.

[0327] 64. The method according to any one of items 50 to 63,

[0328] wherein each of the plurality of oligonucleotide barcodes comprises a linker functional group,

[0329] wherein the synthetic particles comprise solid support functional groups, and

[0330] wherein the support functional group and the linker functional group are associated with each other.

[0331] 65. A method as described in item 64, wherein the linker functional group and the support functional group are individually selected from the group consisting of: C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof.

[0332] 66. A kit comprising:

[0333] a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences;

[0334] terminal deoxynucleotidyl transferase or ligase; and

[0335] A DNA polymerase lacking at least one of a 5' to 3' exonuclease activity and a 3' to 5' exonuclease activity.

[0336] 67. The kit of claim 66, further comprising a plurality of oligonucleotides comprising complements of the target binding region.

[0337] 68. The kit of item 67, wherein the plurality of oligonucleotides comprising the complement of the target binding region are configured to be attached to the 3' end of a DNA molecule, such as a cDNA molecule.

[0338] 69. A kit as described in item 66, wherein the DNA polymerase comprises a Klenow fragment.

[0339] 70. A kit as described in any of items 66-67, comprising a buffer.

[0340] 71. A kit as described in any of items 66-68, comprising a column.

[0341] 72. A kit as described in any of items 66-71, comprising one or more reagents for a reverse transcription reaction.

[0342] 73. A kit as described in any of items 66-72, comprising one or more reagents for an amplification reaction.

[0343] 74. A kit as described in any of items 66-73, wherein the target binding region comprises a gene-specific sequence, an oligo(dT) sequence, a random polymer, or any combination thereof.

[0344] 75. A kit as described in any of items 66-74, wherein the oligonucleotide barcodes contain the same sample marker and / or the same cell marker.

[0345] 76. A kit as described in item 75, wherein each sample marker and / or cell marker of the plurality of oligonucleotide barcodes comprises at least 6 nucleotides.

[0346] 77. A kit as described in any of items 66-75, wherein each molecular tag of the plurality of oligonucleotide barcodes comprises at least 6 nucleotides.

[0347] 78. A kit as described in any of items 66-77, wherein at least one of the multiple oligonucleotide barcodes is immobilized on the synthetic particle.

[0348] 79. A kit as described in any of items 66-78, wherein at least one of the multiple oligonucleotide barcodes is partially fixed on the synthetic particle.

[0349] 80. A kit as described in any of items 66-79, wherein at least one of the multiple oligonucleotide barcodes is enclosed in the synthetic particle.

[0350] 81. A kit as described in any of items 66-80, wherein at least one of the multiple oligonucleotide barcodes is partially enclosed in the synthetic particle.

[0351] 82. A kit as described in any of items 66-81, wherein the synthetic particles are destructible.

[0352] 83. A kit as described in any of items 66-82, wherein the synthetic particles comprise beads.

[0353] 84. A kit as described in item 83, wherein the beads comprise cross-linked agarose beads, streptavidin beads, agarose beads, magnetic beads, conjugated beads, protein A conjugated beads, protein G conjugated beads, protein A / G conjugated beads, protein L conjugated beads, oligo(dT) conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads or any combination thereof.

[0354] 85. A kit as described in any of items 66-84, wherein the synthetic particles comprise a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof.

[0355] 86. A kit as described in any of items 66-85, wherein the synthetic particles comprise destructible hydrogel particles.

[0356] 87. A kit according to any one of items 66 to 86,

[0357] wherein each of the plurality of oligonucleotide barcodes comprises a linker functional group,

[0358] wherein the synthetic particles comprise solid support functional groups, and

[0359] wherein the support functional group and the linker functional group are associated with each other.

[0360] 88. A kit as described in item 87, wherein the linker functional group and the support functional group are individually selected from the following group, which consists of: C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones.

Claims

1. A method for attaching an oligonucleotide barcode to a nucleic acid target in a sample, the method comprising: barcoding copies of the nucleic acid target in the sample using a plurality of oligonucleotide barcodes to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and a complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem-loop; and The 3' ends of the plurality of barcoded nucleic acid molecules are extended to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each of which comprises the molecular tag and a complement of the molecular tag.

2. The method of claim 1, further comprising: The quantity of the nucleic acid target in the sample is determined based on the quantity of molecular tags having different sequences, their complements, or a combination thereof, associated with the plurality of extended barcoded nucleic acid molecules.

3. A method for determining the amount of a target in a sample, the method comprising: barcoding copies of a nucleic acid target in a sample using a plurality of oligonucleotide barcodes to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising a sequence of the nucleic acid target, a molecular marker, and a target binding region, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of barcoded nucleic acid molecules to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and a complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem-loop; extending the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the molecular tag and a complement of the molecular tag; and The quantity of the nucleic acid target in the sample is determined based on the quantity of complementary sequences of the molecular tags having different sequences associated with the plurality of extended barcoded nucleic acid molecules.

4. The method of any one of claims 1-3, wherein barcoding the copies of the plurality of targets comprises: contacting a copy of the nucleic acid target with the plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a target binding region capable of hybridizing to the nucleic acid target; and Copies of the nucleic acid target hybridized to the oligonucleotide barcode are extended to generate a plurality of barcoded nucleic acid molecules.

5. The method of any one of claims 1-3, wherein barcoding the copies of the plurality of targets comprises: contacting a copy of the nucleic acid target with the plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises the target binding region, wherein the target binding region hybridizes to the nucleic acid target; and Copies of the nucleic acid target hybridized to the oligonucleotide barcode are extended to generate a plurality of barcoded nucleic acid molecules.

6. The method according to any one of claims 1 to 5, The method comprises amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules, wherein attaching said oligonucleotide comprising said complement of said target binding region comprises: The oligonucleotide comprising the complement of the target binding region is attached to the plurality of amplified barcoded nucleic acid molecules to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and the complement of the target binding region.

7. The method according to any one of claims 2 to 6, The method includes amplifying the plurality of extended barcoded nucleic acid molecules to produce a plurality of singly labeled nucleic acid molecules, each singly labeled nucleic acid molecule comprising the complement of the molecular tag; Wherein determining the amount of the nucleic acid target in the sample comprises: The quantity of the nucleic acid target in the sample is determined based on the quantity of complementary sequences of the molecular labels having different sequences associated with the plurality of singly labeled nucleic acid molecules.

8. The method according to any one of claims 2 to 6, The method comprises amplifying the plurality of extended barcoded nucleic acid molecules to generate copies of the plurality of extended barcoded nucleic acid molecules, Wherein determining the amount of the nucleic acid target in the sample comprises: The quantity of the nucleic acid target in the sample is determined based on the quantity of complementary sequences of the molecular tags having different sequences associated with the copies of the plurality of extended barcoded nucleic acid molecules.

9. A method for determining the amount of a nucleic acid target in a sample, the method comprising: contacting a copy of a nucleic acid target in a sample with a plurality of oligonucleotide barcodes, wherein each of the plurality of oligonucleotide barcodes comprises a molecular marker and a target binding region capable of hybridizing to the nucleic acid target, and wherein at least 10 of the plurality of oligonucleotide barcodes comprise different molecular marker sequences; extending copies of the nucleic acid target hybridized to the oligonucleotide barcode to produce a plurality of nucleic acid molecules, each nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target; amplifying the plurality of barcoded nucleic acid molecules to produce a plurality of amplified barcoded nucleic acid molecules; attaching an oligonucleotide comprising a complement of the target binding region to the plurality of amplified barcoded nucleic acid molecules to generate a plurality of barcoded nucleic acid molecules, each barcoded nucleic acid molecule comprising the target binding region and a complement of the target binding region; hybridizing the target binding region and a complement of the target binding region within each of the plurality of barcoded nucleic acid molecules to form a stem-loop; extending the 3' ends of the plurality of barcoded nucleic acid molecules to extend the stem-loop to generate a plurality of extended barcoded nucleic acid molecules, each extended barcoded nucleic acid molecule comprising the molecular tag and a complement of the molecular tag; amplifying the plurality of extended barcoded nucleic acid molecules to produce a plurality of singly labeled nucleic acid molecules, each singly labeled nucleic acid molecule comprising the complement of the molecular tag; and The quantity of the nucleic acid target in the sample is determined based on the quantity of complementary sequences of the molecular labels having different sequences associated with the plurality of singly labeled nucleic acid molecules.

10. The method of any one of claims 7-9, wherein after extending the 3' ends of the plurality of barcoded nucleic acid molecules, the molecular tag is hybridized with the complement of the molecular tag, the method comprising denaturing the plurality of extended barcoded nucleic acid molecules and then amplifying the plurality of extended barcoded nucleic acid molecules to produce the plurality of singly labeled nucleic acid molecules.